Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID:ssptaea11624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG	0.6	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG	06	FSTA enhanced with new thesaurus edition
NEWS		AUG		CA/CAplus enhanced with additional kind codes for granted
	•	1100		patents
NEWS	5	AUG	20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS		AUG		Full-text patent databases enhanced with predefined
	۰	*****	-	patent family display formats from INPADOCDB
NEWS	7	AUG	27	USPATOLD now available on STN
NEWS	8	AUG	28	CAS REGISTRY enhanced with additional experimental
		*****		spectral property data
NEWS	9	SEP	0.7	STN AnaVist, Version 2.0, now available with Derwent
	-			World Patents Index
NEWS	10	SEP	13	FORIS renamed to SOFIS
NEWS	11	SEP	13	INPADOCDB enhanced with monthly SDI frequency
NEWS		SEP		CA/CAplus enhanced with printed CA page images from
			-	1967-1998
NEWS	13	SEP	17	CAplus coverage extended to include traditional medicine
				patents
NEWS	14	SEP	24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT	02	CA/CAplus enhanced with pre-1907 records from Chemisches
				Zentralblatt
NEWS	16	OCT	19	BEILSTEIN updated with new compounds
NEWS		NOV		Derwent Indian patent publication number format enhanced
NEWS	18	NOV	19	WPIX enhanced with XML display format
NEWS	19	NOV	30	ICSD reloaded with enhancements
NEWS	20	DEC	04	LINPADOCDB now available on STN
NEWS	21	DEC	14	BEILSTEIN pricing structure to change
NEWS	22	DEC	17	USPATOLD added to additional database clusters
NEWS	23	DEC	17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC	17	DGENE now includes more than 10 million sequences
NEWS	25	DEC	17	TOXCENTER enhanced with 2008 MeSH vocabulary in
				MEDLINE segment
NEWS	26	DEC	17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC	17	CA/CAplus enhanced with new custom IPC display formats
NEWS	28	DEC	17	STN Viewer enhanced with full-text patent content
				from USPATOLD
NEWS	29	JAN	02	STN pricing information for 2008 now available
NEWS	30	JAN	16	CAS patent coverage enhanced to include exemplified
				prophetic substances
NEWS	31	JAN	28	USPATFULL, USPAT2, and USPATOLD enhanced with new

custom IPC display formats

NEWS 32 JAN 28 MARPAT searching enhanced

NEWS 33 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication

NEWS 34 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements

NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS 37 FEB 20 PCI now available as a replacement to DPCI

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 20:25:33 ON 22 FEB 2008

=> file reg

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 20:25:48 ON 22 FEB 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2008 HIGHEST RN 1005032-28-9 DICTIONARY FILE UPDATES: 21 FEB 2008 HIGHEST RN 1005032-28-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading C:\Program Files\Stnexp\Queries\10518114allow.str



```
chain nodes: 13 16 17 18 19 20 21 22 23 24 31
ring nodes: 12 3 4 5 6 7 8 9 10 11 12 14 15
chain bonds: 3-11 7-20 7-21 8-13 8-22 9-17 9-18 10-16 12-19 13-31 14-23 14-24
ring bonds: 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 10-14 11-12 12-15
14-15
exact/norm bonds: 1-2 1-6 2-3 3-4 3-11 4-5 5-6 7-8 7-12 7-20 7-21 8-9 8-13 8-22 9-10
9-17 9-18 10-11 10-14 10-16 11-12 12-15 12-19 13-31 14-15 14-23 14-24
isolated ring systems: containing 1: 7:
```

G1:C,N


G2:C.H

Match level: 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> d 11 L1 HAS NO ANSWERS

LI HAS NO ANSWERS
L1 STR



G1 C,N G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s 11 full

FULL SEARCH INITIATED 20:26:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 110328 TO ITERATE

100.0% PROCESSED 110328 ITERATIONS SEARCH TIME: 00.00.01 214 ANSWERS

L2 214 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 178.82 179.03

FILE 'CAPLUS' ENTERED AT 20:26:52 ON 22 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 22 Feb 2008 VOL 148 ISS 9
FILE LAST UPDATED: 21 Feb 2008 (20080221/ED)
```

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s 12 full
L3 19 L2
```

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:757385 CAPLUS

DOCUMENT NUMBER: 147:166304

TITLE: Preparation of heterocyclic compounds as janus kinase

3 inhibitors

INVENTOR(S): Inoue, Takayuki; Tanaka, Akira; Nakai, Kazuo; Sasaki,

Hiroshi; Takahashi, Fumie; Shirakami, Shohei; Hatanaka, Keiko; Nakajima, Yutaka; Mukovoshi,

Koichiro; Hamaguchi, Hisao; Kunikawa, Shigeki;

Higashi, Yasuyuki
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan

SOURCE: PCT Int. Appl., 266pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PAT	PATENT NO.				KIND DATE				APPL	ICAT	I NOI	NO.		DATE			
WO :	WO 2007077949			A1 20070712				WO 2	006-		20061225						
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,
		KΡ,	KR,	ΚZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,
		MN,	MW,	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,
		RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ΤJ,	TM,	TN,	TR,	TT,
		TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	zw						
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ΒJ,
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG,	BW,	GH,
		GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,
		KG,	KZ,	MD,	RU,	ТJ,	TM										
ORITY	APP	LN.	INFO	.:						JP 2	005-	378858 A 2005122					228

PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 147:166304 GI

AB The title heterocyclic compds. I [wherein X = N or (un)substituted CH; M = a bond or CH2; R1 and R2 = independently H or (un)substituted alkyl; R41 = H or (un)substituted heteroaryl; R42 = an (un)substituted bridged ring

group; R5 = halo, CN, acyl, etc.; or R4l and R5 form a ring.] or pharmaceutically acceptable salts thereof were prepared as janus kinase 3 (JAK3) inhibitors. For example, II was prepared in a multi-step synthesis. The compds. are useful for treating or preventing various immune diseases, such as rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, etc.

1T 94417-13-9P 944122-15-0P 944122-18-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of heterocyclic compds. as JAK3 inhibitors)

RN 944117-13-9 CAPLUS CN 1H-Pyrrolo[2,3-b]py

1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-amino-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944122-15-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-nitro-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944122-18-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-bromo-2-pyrimidiny1)-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

Relative stereochemistry.

- RN 944117-22-0 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-[5-(dimethylamino)-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944117-26-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-cyano-2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944117-44-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-[5-(trifluoromethyl)-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944117-52-6 CAPLUS

<12/04/2007>

Erich Leese

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-N-methyl- (CA INDEX NAME)

Relative stereochemistry.

- RN 944118-18-7 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[((3-exo)-8-(2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944118-20-1 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944118-46-1 CAPLUS

<12/04/2007>

Erich Leese

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-[5-[(dimethylamino)carbonyl]-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]amino]-(CA INDEX NAME)

Relative stereochemistry.

- RN 944121-64-6 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-[5-(hydroxymethyl)-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944121-87-3 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(4-cyano-2-pyridiny1)-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944121-88-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(4-cyanophenyl)-8-azabicyclo[3,2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944121-89-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-chloro-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944121-90-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(4-pyridinyl)-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

<12/04/2007>

Erich Leese

RN 944121-91-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-acety1-2-pyridiny1)-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944121-93-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3-exo)-3-[[5-(aminocarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]-6-azabicyclo[3.2.1]oct-8-yl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM

CRN 944121-92-0

CMF C21 H22 N6 O3

Relative stereochemistry.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 944121-94-2 CAPLUS

CN 1H-Pyrrolo(2,3-b)pyridine-5-carboxamide, 4-[((3-exo)-8-(5-fluoro-2-pyridinyl)-8-azabicyclo(3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944121-98-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-cyclohexyl-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-13-8 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(6-chloro-5-cyano-3-fluoro-2-pyridiny1)-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-14-9 CAPLUS
- CN 3-Pyridinearboxylic acid, 6-[(3-exo)-3-[[5-(aminocarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]-8-azabicyclo[3.2.1]oct-8-yl]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.

RN 944122-16-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(5-cyano-2-pyrazinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944122-17-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[((3-exo)-8-(5-nitro-2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-19-4 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(6-cyano-3-pyridazinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-21-8 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(2-cyano-5-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-23-0 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-[5-(aminocarbonyl)-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944122-25-2 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[(3-endo)-3-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-H-pyrrolo[2,3-b]pyridin-4-yl]amino]-8-azabicyclo[3.2.1]oct-8-yl]- (CA NDEX NAME)

Relative stereochemistry.

RN 944122-26-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-endo)-8-(3-nitro-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-28-5 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-(3-chloro-5-cyano-2-pyridiny1)-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-29-6 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-[6-(hydroxymethyl)-3-pyridazinyl]-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- RN 944122-31-0 CAPLUS
- CN 3-Pyridazinecarboxylic acid, 6-[(3-exo)-3-[[5-(aminocarbonyl)-1H-pyrrolo[2,3-b]pyridan-4-y1]amino]-8-azabicyclo[3.2.1]oct-8-y1]-, methyl ester (CA INDEX NAME)

Relative stereochemistry.

RN 944122-32-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-exo)-8-[6-(aminocarbony1)-3-pyridaziny1]-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

RN 944135-23-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-endo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- 944135-24-4 CAPLUS RN
- 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-endo)-8-(5-nitro-2-CN pyridiny1)-8-azabicyclo[3.2.1]oct-3-y1]amino]- (CA INDEX NAME)

Relative stereochemistry.

- 944135-25-5 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(3-endo)-8-[5-(trifluoromethyl)-2-pyridinyl]-8-azabicyclo[3.2.1]oct-3-yl]amino]- (CA INDEX NAME)

Relative stereochemistry.

- IT 944122-57-0P 944123-89-1P
 - RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (intermediate; preparation of heterocyclic compds. as JAK3 inhibitors) 944122-57-0 CAPLUS
- RN
- CN Carbamic acid, N-[(3-exo)-8-[5-(trifluoromethyl)-2-pyridinyl]-8azabicyclo[3.2.1]oct-3-y1]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.

RN 944123-89-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[5-(trifluoromethy1)-2-pyridiny1]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:409606 CAPLUS

DOCUMENT NUMBER: 146:401834

TITLE: Preparation of azabicyclo[2.2.1]octane derivatives as

pesticides

INVENTOR(S): Hamamoto, Isami; Takahashi, Jun; Yano, Makio;

Kawaguchi, Masahiro; Hanai, Daisuke; Iwasa, Takao

PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 97pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

OTHER SOURCE(S):

GI

PA'	PATENT NO.						DATE		APPLICATION NO.						DATE			
WO	2007	2007040280					2007	20070412		WO 2	006-	JP32	0126		2	0061	006	
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	KP,	
		KR,	KZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	
		MW,	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	
		RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW								
	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,	
		GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,	
		KG,	KZ,	MD,	RU,	TJ,	TM											
PRIORIT	Y APP	LN.	INFO	. :						JP 2	005-	2941	26		A 2	0051	006	
										JP 2	005-	2941	27		A 2	0051	006	
										JP 2	005-	2978	03	- 1	A 2	0051	012	
									JP 2005-297804						A 2	0051	012	

JP 2006-16877

JP 2006-182314

II

A 20060125

A 20060630

F3C

MARPAT 146:401834

AB The title compds. I [wherein Cyl = (un)substituted heterocyclyl; Cy2 = (un)substituted cyclyl, heterocyclyl, etc.; n = 0-9; X = 0, S, S0, S02, or (un)substituted NH; R = OH, halo, (un)substituted NH2, etc.; or two R's

form a ring] are prepared as pest control agents. For example, the compound II was prepared in a multi-step synthesis. Some of compds. I showed excellent pesticidal activities in tests.

933797-20-7P 933797-68-3P 933797-69-4P

933797-70-7P 933797-71-8P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES

(Uses) (pesticide; preparation of azabicyclo[2.2.1]octane derivs. as pesticides)

933797-20-7 CAPLUS

CN Benzoic acid, 5-(trifluoromethyl)-2-[(3-endo)-3-[[5-(trifluoromethyl)-2pyridinyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]-, 1-methylethyl ester (CA INDEX NAME)

Relative stereochemistry.

RN 933797-68-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-propoxy-4-(trifluoromethoxy)phenyl]-8-[5-(trifluoromethy1)-2-pyridiny1]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

RN 933797-69-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-methoxy-4-(trifluoromethoxy)phenyl]-8-[5-(trifluoromethyl)-2-pyridinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

RN 933797-70-7 CAPLUS

<12/04/2007>

Erich Leese

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-propoxy-4-(trifluoromethy1)pheny1]-8-[5-(trifluoromethy1)-2-pyridiny1]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

- RN 933797-71-8 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-methyl-3-(trifluoromethyl)phenyl]-8[5-(trifluoromethyl)-2-pyridinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

REFERENCE COUNT:

7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:405401 CAPLUS

DOCUMENT NUMBER: 146:421857

TITLE: Preparation of bridged cyclic amine compounds as pest

control agents

Hamamoto, Isami; Takahashi, Jun; Yano, Makio; INVENTOR(S):

Kawaguchi, Masahiro; Hanai, Daisuke; Iwasa, Takao

PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan PCT Int. Appl., 98pp.

SOURCE:

CODEN: PIXXD2 DOCUMENT TYPE: Patent.

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2 PATENT INFORMATION:

	KIND DATE			APPLICATION NO.													
	2007040282																
	W: RW:	CN, GE, KR, MW, RU, UA, AT, IS, CF,	CO, GH, KZ, MX, SC, UG, BE, IT, CG,	CR, GM, LA, MY, SD, US, BG, LT, CI,	CU, HN, LC, MZ, SE, UZ, CH, LU, CM,	CZ, HR, LK, NA, SG, VC, CY, LV, GA,	AU, DE, HU, LR, NG, SK, VN, CZ, MC, GN, NA,	DK, ID, LS, NI, SL, ZA, DE, NL, GQ,	DM, IL, LT, NO, SM, ZM, DK, PL, GW,	DZ, IN, LU, NZ, SV, ZW EE, PT, ML,	EC, IS, LV, OM, SY, ES, RO, MR,	EE, JP, LY, PG, TJ, FI, SE, NE,	EG, KE, MA, PH, TM, FR, SI, SN,	ES, KG, MD, PL, TN, GB, SK, TD,	FI, KM, MG, PT, TR, GR, TR,	GB, KN, MK, RO, TT, HU, BF, BW,	GD, KP, MN, RS, TZ, IE, BJ, GH,
					MW, RU,			SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
PRIORITY .	APPI	.N. :	INFO	.:						JP 2: JP 2: JP 2: JP 2: JP 2: JP 2:	005- 005- 005- 006-	2941: 2978: 2978: 1687	27 03 04 7		A 2 A 2 A 2 A 2	0051 0051 0051 0051 0060 0060	006 012 012 125

OTHER SOURCE(S): MARPAT 146:421857

GI

- AB Title compds. I [Cyl = (un)substituted aromatic ring; X = oxygen, sulfur, (un)substituted nitrogen, etc.; Rla and R2a, Rla and R4a, R2a and R3a, or R3a and R4a may combine to form a saturated ring; Rla-R4a, Rlb-R4b and R5 = H, hydroxy, halo, etc.; Cy2 = (un)substituted aromatic ring; when Rla and R2a may combine to form saturated ring and Cyl is a (un)substituted PR and Cy2 is a pyridin-2-yl, Cy2 is a pyridin-2-yl substituted with one or more cyano groups.], salts or N-oxides thereof were prepared For example, reaction of tropine with 2-chloro-5-trifluoromethylbyridine followed by treatment with 2,2,2-trichloroethyl chloroformate, reduction using Zn/acetic acid and O-arylation with 2-fluoro-5-trifluoromethylbersleddehyde afforded compound II [R = CHO; R! = CF3] controlled two-spotted spider mite by 100%.
- IT 933797-20-7P 933797-68-3P 933797-69-4P 933797-70-7P 933797-1-8P
 - RI: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES
- (preparation of bridged cyclic amine compds. as pest control agents) ${\tt RN} \quad 933797-20-7 \quad {\tt CAPLUS}$
- CN Benzoic acid, 5-(trifluoromethyl)-2-[(3-endo)-3-[[5-(trifluoromethyl)-2-pyridinyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]-, 1-methylethyl ester (CA INDEX NAME)

Relative stereochemistry.

RN 933797-68-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-propoxy-4-(trifluoromethoxy)pheny1]-8-[5-(trifluoromethyl)-2-pyridinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

RN 933797-69-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-methoxy-4-(trifluoromethoxy)phenyl]-8-[5-(trifluoromethyl)-2-pyridinyl]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

RN 933797-70-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-propoxy-4-(trifluoromethyl)phenyl]-8-[5-(trifluoromethyl)-2-pyridinyl]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

RN 933797-71-8 CAPLUS

<12/04/2007>

Erich Leese

CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[2-methy1-3-(trifluoromethy1)pheny1]-8[5-(trifluoromethy1)-2-pyridiny1]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

REFERENCE COUNT:

15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

GI

L3 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1124114 CAPLUS

DOCUMENT NUMBER: 145:455030

TITLE: Preparation of substituted heteroaryl CB1 antagonists

INVENTOR(S): Yuan, Jun; Guo, Qin; Zhao, He; Hu, Shaojing;

Whitehouse, Darren; Fringle, Wallace; Mao, Jianmin; Maynard, George; Hammer, Jack; Wustrow, David; Li,

Maynard, George; Hammer, Jack; Wustrow, David Hongbin

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 447pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		DATE		CATION NO								
WO 2006113704 WO 2006113704	A2	20061026				20060418						
W: AE, AG,			DA DD	DC DD D	W DV I	D7 C7 CU						
						FI, GB, GD,						
						KN, KP, KR,						
						MN, MW, MX,						
						SC, SD, SE,						
SG, SK,	SL, SM, SY	I, TJ, TM,	TN, TR,	TT, TZ, U	A, UG,	US, UZ, VC,						
VN, YU,	ZA, ZM, ZV	ñ										
RW: AT, BE,	BG, CH, CY	Y, CZ, DE,	DK, EE,	ES, FI, F	R, GB,	GR, HU, IE,						
IS, IT,	LT. LU. LV	J. MC. NL.	PL. PT.	RO. SE. S	I. SK.	IR, BF, BJ,						
CF, CG,	CI, CM, GA	A. GN. GO.	GW. ML.	MR. NE. S	N. TD.	IG, BW, GH,						
						AM, AZ, BY,						
	MD, RU, TJ		,,	,, -	,,	,,						
CA 2606288			C7 20	06-260629	0	20060419						
US 2007078135												
EP 1871762												
R: AT, BE,												
IS, IT,	LI, LT, LU	J, LV, MC,										
PRIORITY APPLN. INFO	:					P 20050418						
			WO 20	06-US1454	8 W	W 20060418						
OTHER SOURCE(S):	MARPA	MARPAT 145:455030										

AB The title compds. I [A = CRl or N; Arl, Ar2 = (un)substituted 5-10 membered carbocycle and heterocycle; X = (un)substituted CH2, O, NH or SOmNH; m = 0-2; Y = (un)substituted alkylene; Z = (un)substituted OH, NH2, SOmNH2, etc.; R1 = H, halo, CN, etc.] which may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders, were prepared E.g., a multi-step synthesis of II, starting from 2,6-dichloropyrazine and 4-(ethylamino)piperidine-4-carboxamide, was given. Exemplified compds. I were tested at CB1 receptor. Thus, II as many other representative compds. I showed IC50 of 2 μM or less. Pharmaceutical compns. and methods for using compds. I to treat disorders responsive to CB1 modulation are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

ΙI

IT 913281-93-3P 913281-94-4P 913281-97-7P 913282-02-7P 913282-12-9P 913282-17-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heteroaryl compds. useful in treatment of diseases responsive to CB1 activation)

RN 913281-93-3 CAPLUS CN Carbamic acid, [8-[

Carbamic acid, [8-[6-(3-chloro-4-pyridinyl)-5-(2,4-difluorophenyl)pyrazinyl]-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9Cl) (CA INDEX NAME)

RN 913281-94-4 CAPLUS

CN Carbamic acid, [8-[5,6-bis(4-chlorophenyl)pyrazinyl]-8azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 913281-97-7 CAPLUS

Carbamic acid, [8-[6-(3-chloro-4-pyridinyl)-5-(4-fluorophenyl)pyrazinyl]-8-CN azabicyclo[3.2.1]oct-3-y1]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN

913282-02-7 CAPLUS Propanamide, N-[8-[5,6-bis(4-chlorophenyl)pyrazinyl]-8-CN azabicvclo[3.2.1]oct-3-v1]-2-methv1- (9CI) (CA INDEX NAME)

RN 913282-12-9 CAPLUS

Propanamide, N-[8-[6-(3-chloro-4-pyridiny1)-5-(2,4-CN difluorophenyl)pyrazinyl]-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl- (9CI) (CA INDEX NAME)

RN

913282-17-4 CAPLUS Propanamide, N-[8-[6-(3-chloro-4-pyridinyl)-5-(4-fluorophenyl)pyrazinyl]-8-CN azabicyclo[3.2.1]oct-3-y1]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:606621 CAPLUS

DOCUMENT NUMBER: 145:63034

TITLE: Preparation of silicon compounds and their use in

medicament

INVENTOR(S): Showell, Graham Andrew; Walsh, Louise Marie; Mandal,

Ajay Kumar

PATENT ASSIGNEE(S): Paradigm Therapeutics Ltd., UK

SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Facent English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PRIORITY APPLN. INFO.:

PATENT NO. KIND DATE APPLICATION NO. DATE WO 2006064277 A1 20060622 WO 2005-GB4905 20051216 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, F1, GB, GE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, Z, LC, LK, LR, LS, LT, LU, LV, LY, LM, MD, MG, MK, MN, MM, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SK, SK, SK, SK, SK, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2005315331 20060622 AU 2005-315331 A1 20051216 CA 2590881 20060622 CA 2005-2590881 20051216 A1 EP 1824863 20070829 EP 2005-820647 20051216 A1 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR CN 101107259 Α 20080116 CN 2005-80043255 20051216 IN 2007DN03844 Α 20070831 IN 2007-DN3844 20070522 KR 2007097468 20071004 KR 2007-714460 20070625 A

GB 2004-27722

WO 2005-GB4905 W 20051216

A 20041217

OTHER SOURCE(S): CASREACT 145:63034; MARPAT 145:63034

Ι

- AB Preparation of title compds., e.g. I (D = (un)substituted alkylene, O, thionyl, sulfonyl, etc.; E, F, G = same or different (un)substituted alkylene, (un)substituted amino, etc.; J = bond, heterocycloalkyl, etc.; K, L = same or different H, alkyl, cycloalkyl, alkoxy, etc.; Ra, K or L taken together as heterocycloalkyl; Ra = H, halo, alkyl, aryl, hydroxy, alkoxy, etc.; Y, Z = same or different H, halo, alkyl, hydroxy, alkoxy, cyano, organosilyl, etc.; ringl and ring2 = same or different arylene, heteroarylene optionally substituted with Ra; at least one of Y and Z includes a Si atom), and their use in therapy is described.
- (preparation of organosily1 compds. and their use in medicament) ${\tt RN} {\tt 891860-56-3} {\tt CAPLUS}$
- Office of the control of the control

REFERENCE COUNT:

2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:1006982 CAPLUS

DOCUMENT NUMBER: 140:59518

TITLE: Preparation of [[(8-azabicyclo[3.2.1]octyl)amino]acety 1]- or [[(9-azabicyclo[3.3.1]nonyl)amino]acetyl]hetero

cyclic carbonitriles as dipeptidyl-peptidase-IV

inhibitors

Aranvi, Peter; Balazs, Laszlo; Bata, Imre; Batori, INVENTOR(S): Sandor; Boronkay, Eva; Kapui, Zoltan; Susan, Edit; Szabo, Tibor; Nagy, Lajos T.; Urban-Szabo, Katalin;

Varga, Marton

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr. SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

										APPLICATION NO.								
WO		1064	56		A2		2003	1224			2003-							
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BE	, BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC	, EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE	, KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN	, MW,	MX,	MZ,	NI,	NO,	NZ,	OM,	
		PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG	, SK,	SL,	TJ,	TM,	TN,	TR,	TT,	
		TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA	, ZM,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ	, TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
		KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG	, CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
											, NL,							
											, GW,							
									HU 2002-2001									
									AU 2003-244880									
BR	2003	0117	71		A 20050329				BR	2003-	1177	20030611 20030611						
EP																		
	R:										, IT,							
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	ΑL	, TR,	BG,	CZ,	EE,	HU,	SK		
CN	1662	530			A		2005	0831		CN	2003-	8138	20030611 20030611 20030611 20041206					
JP	2005	5323	69		T		2005	1027		JΡ	2004-	5132	88		2	0030	511	
NZ	5376	33	0.50		A		2006	0831		NZ	2003-	5376	33		2	0030	511	
IN	2004	KNOT	852		A		2005	1230		TM	2004-	KN18	52		2	0041	206	
4M	2004	0022	0 /		27		2000	0030		AP.	2004-	2201				0041	201	
	7567						2007				2004-							
MX	2004	PAIZ	691		A		2005	0812			2004-							
NO	2005	0001	99		A		2005	0304			2005-					0050		
US	2005 APP	1539	/3 TMB0		AI		2005	0/14			2005-							
JKIT:	I APP	PM.	TMEO	. :							2002-					0020 0030		
ER SO	OURCE	(S):			MARI	PAT	140:	5951:		WU	2003-	n041			w Z	0030	011	

OTHER SOURCE(S): MARPAT 140:59518

GI

AB Title compds. I [wherein R = (un)substituted N-containing 1- or 2-ring aromatic moieties, p-tolylsulfonyl, RlaCH2, or RlbCO, Rla = H or (un)substituted alkyl, Ph, PhCH2, Ph(CH2)2, PhCH-CH, naphthyl, pyridyl, etc.; Rlb = (un)substituted alkyl, Ph, PhCR2, Ph(CH2)2, PhCH-CH, naphthyl, pyridyl, etc.; B = 8-azabicyclo[3.2.1]octyl or 9-azabicyclo[3.3.1]nonyl; Z = thiazolidinediyl, (hydroxy or xoo)pyrrolidinediyl, oxazolidinediyl, or dihydropyrrolidinediyl, and salts, isomers, tautomers, hydrates, or solvates thereof) were prepared as dipeptidyl-peptidase-IV (DPP-IV) inhibitors. These compds. contain tropane building blocks. For example, substitution of tert-Bu 8-benzyl-8-azabicyclo[3.2.1]oct-3-yl-exo-carbamate with 2-chloropyrimidine gave the 8-pyrimidinyl derivative (67%), which was converted to the amine (77%) using IFA. Amidation of (4R)-3-(tert-butoxycarbonyl)thiazolidine-4-carboxylic acid (88%), followed by deprotection (81%), addition of chloracetyl chloride (75%), and reduction of

the

amide to the nitrile (43%), gave (4R)-3-(2-chloroacety])thiazolidine-4-carbonitrile. Coupling of 8-(2-pyrimidiny)1-8-zasibicyclo[3.2.1]oct-3-yl-exo-amine with the nitrile using TEA in MeCN afforded II (53%). Compds. of the invention show low IC50 values for DPP-IV enzyme inhibitory activity in comparison with known compds. and are strong, long-acting enzyme inhibitors (no data). Thus, I and their pharmaceutical compns. are useful for the treatment of DPP-IV related diseases.

```
IT 637018-37-2P 637018-38-3P 637018-39-4P 637018-40-7P 637018-41-8P 637018-42-9P
```

637018-43-0P 637018-44-1P 637018-45-2P 637018-53-2P 637018-54-3P 637018-55-4P

637018-53-2P 637018-54-3P 637018-55-4P 637018-56-5P 637018-57-6P 637018-58-7P

637018-59-8P 637018-60-1P 637018-74-7P 637018-84-9P 637019-04-6P 637019-05-7P

637018-84-9P 637019-04-6P 637019-05-7P 637330-99-5P 637331-04-5P 637331-18-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [[(8-azabicyclo[3.2.1]octyl)amino]acetyl]- or [[(9-azabicyclo[3.3.1])nonyl)amino]acetyl]heterocyclic carbonitriles as DPP-IV inhibitors)

RN 637018-37-2 CAPLUS

CN 4-Thiazolidinecarbonitrile, 3-[[[(3-exo)-8-(2-pyrimidinyl)-8azabicyclo[3.2.1]oct-3-yllamino|acetyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 637018-38-3 CAPLUS

CN 4-Thiazolidinecarbonitrile, 3-[[[(3-exo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● 2 HC1

RN 637018-39-4 CAPLUS

CN 4-Thiazolidinecarbonitrile, 3-[[[(3-exo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●2 HC1

RN 637018-40-7 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(5-nitro-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 637018-41-8 CAPLUS

CN 4-Oxazolidinecarbonitrile, 3-[[[(3-exo)-8-(2-pyrimidiny1)-8azabicyclo[3.2.1]oct-3-y1]amino]acetyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

- RN 637018-42-9 CAPLUS
- CN lH-Pyrrole-2-carbonitrile, l-[[[(3-exo)-8-(5-cyano-2-pyridiny1)-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-2,5-dihydro-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● 2 HC1

- RN 637018-43-0 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4-oxo-1-[[[(3-exo)-8-(2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● 2 HCl

RN 637018-44-1 CAPLUS

CN 4-Thiazolidinecarbonitrile, 3-[[[(3-exo)-8-(5-nitro-2-pyridinyl)-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

RN 637018-45-2 CAPLUS

CN 4-Thiazolidinecarbonitrile, 3-[[[(3-exo)-8-(5-bromo-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 637018-53-2 CAPLUS

CN 4-Thiazolidinecarbonitrile, 3-[[[(3-endo)-9-(2-pyrimidinyl)-9-azabicyclo[3.3.1]non-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

<12/04/2007>

Erich Leese

●2 HC1

RN 637018-54-3 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

RN 637018-55-4 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

● 2 HC1

- RN 637018-56-5 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(5-bromo-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 637018-57-6 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[(3-exo)-8-(5-cyanopyrazinyl)-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 637018-58-7 CAPLUS
- CN 3-Pyridazinecarbonitrile, 6-[(3-exo)-3-[[2-(2-cyano-1-pyrrolidiny1)-2oxoethy1]amino]-8-azabicyclo[3.2.1]oct-8-y1]- (CA INDEX NAME)

Relative stereochemistry.

RN 637018-59-8 CAPLUS

CN 3-Pyridazinecarboxylic acid, 6-[(3-exo)-3-[[2-(2-cyano-1-pyrrolidiny1)-2-oxoethyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

● HCl

- RN 637018-60-1 CAPLUS
- CN 3-Pyridazinecarboxamide, 6-[(3-exo)-3-[[2-(2-cyano-1-pyrrolidiny1)-2-oxoethy1]amino]-8-azabicyclo[3.2.1]oct-8-y1]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ &$$

● HCl

- RN 637018-74-7 CAPLUS
- CN 4-Oxazolidinecarbonitrile, 3-[[[(3-exo)-8-(3-cyano-6-methyl-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

●2 HC1

- RN 637018-84-9 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4-hydroxy-1-[[[(3-exo)-8-(2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

- RN 637019-04-6 CAPLUS
- CN 4-Thiazolidinecarbonitrile, 3-[[(3-exo)-8-(5-cyano-2-pyridinyl)-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

- RN 637019-05-7 CAPLUS
- CN 4-Thiazolidinecarbonitrile, 3-[[(3-exo)-8-pyrazinyl-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

- RN 637330-99-5 CAPLUS
 - CN 4-Thiazolidinecarbonitrile, 3-[[[(3-endo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 637331-04-5 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-endo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 637331-18-1 CAPLUS
- CN 4-Thiazolidinecarbonitrile, 3-[[[(3-endo)-8-(5-cyano-2-pyridinyl)-8azabicyclo[3.2.1]oct-3-y1]amino]acetyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/513699

```
TT 596816-99-8P 596817-00-4P 596817-03-7P 596817-04-8P 596817-10-6P 596817-11-7P 596817-14-0P 596817-51-1P 596817-66-2P 596817-62-2P 596817-72-0P 596817-70-8P 596817-71-9P 596817-72-0P 596817-73-6P 596817-73-92-4P 637331-09-0P 637331-13-6P
```

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of [[(8-azabicyclo[3.2.1]octyl)amino]acetyl]- or

[[(9-azabicyclo[3.3.1]nonyl)amino]acetyl]heterocyclic carbonitriles as DPP-IV inhibitors)

RN 596816-99-8 CAPLUS

CN Carbamic acid, [(3-exo)-8-(2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-00-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(2-pyrimidiny1)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-03-7 CAPLUS

CN Carbamic acid, [(3-exo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-04-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-pyrazinyl-, (3-exo)- (9CI) (CA INDEX NAME)

RN 596817-10-6 CAPLUS

CN Carbamic acid, [(3-exo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-11-7 CAPLUS
- CN Carbamic acid, [(3-exo)-8-(5-nitro-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

$$\bigcap_{0 \geq N} \bigcap_{N} \bigcap_{S} \bigcap_{H} \bigcap_{OBu-t} \bigcap_{S} \bigcap_{C} \bigcap_$$

- RN 596817-14-0 CAPLUS
- CN Carbamic acid, [(3-exo)-8-(5-bromo-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-15-1 CAPLUS
- CN Carbamic acid, {(3-exo)-8-(3-cyano-6-methyl-2-pyridinyl)-8azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 596817-16-2 CAPLUS

CN Carbamic acid, [(3-exo)-8-(6-cyano-3-pyridaziny1)-8-azabicyclo[3.2.1]oct-3-y1]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-22-0 CAPLUS

CN Carbamic acid, ((3-exo)-8-(5-cyanopyrazinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-37-7 CAPLUS

CN Carbamic acid, [(3-endo)-9-(2-pyrimidinyl)-9-azabicyclo[3.3.1]non-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.


- RN 596817-66-2 CAPLUS
- CN 3-Pyridinecarbonitrile, 6-[(3-exo)-3-amino-8-azabicyclo[3.2.1]oct-8-y1]-(CA INDEX NAME)

- RN 596817-67-3 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(5-nitro-2-pyridinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-70-8 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(5-bromo-2-pyridinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



- RN 596817-71-9 CAPLUS
- CN 3-Pyridinecarbonitrile, 2-[(3-exo)-3-amino-8-azabicyclo[3.2.1]oct-8-yl]-6-methyl- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-72-0 CAPLUS

CN 3-Pyridazinecarbonitrile, 6-[(3-exo)-3-amino-8-azabicyclo[3.2.1]oct-8-y1]-(CA INDEX NAME)

Relative stereochemistry.

RN 596817-78-6 CAPLUS

CN Pyrazinecarbonitrile, 5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]oct-8-y1]-(9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-92-4 CAPLUS

CN 9-Azabicyclo[3.3.1]nonan-3-amine, 9-(2-pyrimidinyl)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 637331-09-0 CAPLUS

<12/04/2007>

Erich Leese

CN Carbamic acid, [(3-endo)-8-(5-cyano-2-pyridiny1)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 637331-13-6 CAPLUS
- CN 3-Pyridinecarbonitrile, 6-[(3-endo)-3-amino-8-azabicyclo[3.2.1]oct-8-y1]-(CA INDEX NAME)

Relative stereochemistry.

L3 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:719461 CAPLUS

DOCUMENT NUMBER: 139:245893

TITLE: Preparation of aminoacetylpyrrolidinecarbonitriles as

inhibitors of DPP-IV

INVENTOR(S): Aranyi, Peter; Balazs, Laszlo; Bata, Imre; Batori, Sandor; Boronkav, Eva; Bovy, Philippe; Kanai, Karoly;

Kapui, Zoltan; Susan, Edit; Szabo, Tibor; Nagy, Lajos T.: Urban-Szabo, Katalin: Varga, Marton

1.; Urban-Szabo, Katalin; Varga, Mart

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; et al.

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.						DATE			APPLICATION NO.					DATE			
							20030912		WO 2003-HU17						20030304			
	W:	CO, GM,	CR, HR,	CU, HU,	CZ,	DE,	DK, IN,	DM, IS,	DZ,	E	B, BG, C, EE, E, KG, N, MW,	ES, KP,	FI, KR,	GB, KZ,	GD,	GE,	GH, LR,	
											K, SL, 4, ZW		TM,	TN,	TR,	TT,	TZ,	
	RW:	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BO	Z, TZ, G, CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
		BF.	BJ.	CF.	CG.	CI.	CM.	GA.	GN.	GC	C, NL, Q, GW,	ML.	MR.	NE.	SN.	TD.	TG	
HU	2002	49		A2 20040830					HU 2002-849					20020306				
CA	2475312				A1 20030912				HU 2002-849 CA 2003-2475312					20030304				
AU	2003209514				A1 20030916				AU 2003-209514					20030304				
EP					A2 20041222				EP 2003-743452					20030304				
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GE	R, IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AI	, TR,	BG,	CZ,	EE,	HU,	SK		
BR	BR 2003007960 CN 1639159 JP 2005529078 NZ 535662 CN 1990486				A 20050215					BR 2003-7960					20030304			
CN	CN 1639159				A 20050713					CN 2003-805263					20030304			
JP	JP 2005529078				T 20050929					JP 2003-572969					20030304			
NZ	NZ 535662				A		2007	0531		NZ	2003-	-5356	62		2	20030	304	
CN	CN 1990486				A		2007	0704		CN	2006-10164020				20030304			
1.00	IW 250978				В		20060311			TW	W 2003-92104/43				4	20030	306	
IN	TM 2004FM01070						20060127			TAT	1 2004 PM1070				20040720			
ZA	ZA 2004006467						20050622			ZA	A 2004-6467				20040813			
MX	MX 2004PA08613				A		2005		MX	MX 2004-PA8613				- 2	20040	906		
NO	NO 2004004221				A		2004		NO	NO 2004-4221				20041005				
US	US 2005130981				A1		2005		US	2005-507005			20050131					
PRIORIT	TA 2004006467 ZA 2004006467 MX 2004PA08613 NO 2004004221 US 2005130981 PRIORITY APPLN. INFO.:									HU	2002-	849			A 2	20020	306	
										CN	2003-	8052	63		A3 2	20030	304	
											2003-					20030		
OTHER C	OTHER COMPORTER.					MADDAT 120.245			2.2									

OTHER SOURCE(S): MARPAT 139:245893

GI

AB Title compde. I [Rl = (un)substituted N heteroarom., thienyl, furyl, CR2Ph, tosyl, acyl; B = N heterocyclic; R2 - H, F] were prepared for use as dipeptidyl peptidase IV (DPP-IV) inhibitors with IC50 ≤ 100 nM, useful in the treatment of diabetes. Thus, the title compound II was prepared from 8 -(2-pyrimidinyl)-8-azabicyclo[3.2.1]ot-3-y1-exo-amine and (25)-1-chloroacetyl-4, 4-difluoro-2-pyrrolidinecarbonitrile, each prepared in several steps.

```
$96817-04-8B $96817-09-3P $96817-10-6B $96817-11-7B $96817-13-9P $96817-13-9P $96817-13-9P $96817-13-9P $96817-13-9P $96817-13-9P $96817-13-9P $96817-13-9P $96817-16-2P $96817-16-2P $96817-18-9P $96817-19-2-0P $96817-23-1P $96817-23-1P $96817-23-1P $96817-35-5P $96817-37-7P $96817-65-1P $96817-65-2P $96817-79-1P $96817-65-2P $96817-79-1P $96817-74-2P $96817-75-3P $96817-39-3P $96817-33-3P $99165-33-3P $99165-33-3P
```

596816-99-8P 596817-00-4P 596817-03-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoacetylpyrrolidinecarbonitriles as inhibitors of DPP-IV)
RN 596816-99-8 CAPLUS
CN Carbanic acid. (3-exo)-8-(2-pyrimidinyl)-8-azabicyclo(3-2 lloct-3-yll-

N Carbamic acid, [(3-exo)-8-(2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-00-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(2-pyrimidinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-03-7 CAPLUS

CN Carbamic acid, [(3-exo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-04-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-pyrazinyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

$$\bigvee_{N}\bigvee_{S}^{R}\bigvee_{NH_{2}}$$

RN 596817-09-3 CAPLUS

CN Carbamic acid, [(3-exo)-8-(2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-10-6 CAPLUS

CN Carbamic acid, [(3-exo)-8-(5-cyano-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

$$\bigcap_{NC} \bigcap_{N} \bigcap_{N} \bigcap_{H} \bigcap_{OBu-t}$$

RN 596817-11-7 CAPLUS

CN Carbamic acid, [(3-exo)-8-(5-nitro-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

$$\bigcap_{0 \geq N} \bigcap_{N} \bigcap_{S} \bigcap_{H} \bigcap_{OBu-t} \bigcap_{S} \bigcap_{C} \bigcap_$$

RN 596817-12-8 CAPLUS

CN Carbamic acid, [(3-exo)-8-(6-chloro-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-13-9 CAPLUS

CN Carbamic acid, [(3-exo)-8-(4-methyl-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

- RN 596817-14-0 CAPLUS
- CN Carbamic acid, [(3-exo)-8-(5-bromo-2-pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-15-1 CAPLUS
- CN Carbamic acid, [(3-exo)-8-(3-cyano-6-methyl-2-pyridinyl)-8azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-16-2 CAPLUS
- CN Carbamic acid, [(3-exo)-8-(6-cyano-3-pyridazinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

10/513699

RN 596817-17-3 CAPLUS

CN Carbamic acid, [(3-exo)-8-(6-chloro-3-pyridazinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-18-4 CAPLUS

CN Carbamic acid, [(3-exo)-8-(4-chloro-2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-19-5 CAPLUS

CN Carbamic acid, [(3-exo)-8-(6-chloropyrazinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-20-8 CAPLUS

CN Carbamic acid, [(3-exo)-8-(2-chloro-4-pyrimidiny1)-8-azabicyclo[3.2.1]oct-3-y1]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-21-9 CAPLUS

CN Carbamic acid, [(3-exo)-8-(6-chloro-4-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-22-0 CAPLUS

CN Carbamic acid, [(3-exo)-8-(5-cyanopyraziny1)-8-azabicyclo[3.2.1]oct-3-y1]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 596817-23-1 CAPLUS

CN Carbamic acid, [(3-exo)-8-[2-(methylthio)-4-pyrimidinyl]-8azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-34-4 CAPLUS
- CN Carbamic acid, [(3-exo)-9-pyraziny1-9-azabicyclo[3.3.1]non-3-y1]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

- RN 596817-35-5 CAPLUS
- CN Carbamic acid, [(3-exo)-9-(5-cyano-2-pyridinyl)-9-azabicyclo[3.3.1]non-3yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-37-7 CAPLUS
- CN Carbamic acid, [(3-endo)-9-(2-pyrimidinyl)-9-azabicyclo[3.3.1]non-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-65-1 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(2-pyridinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-66-2 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[(3-exo)-3-amino-8-azabicyclo[3.2.1]oct-8-yl]-(CA INDEX NAME)

Relative stereochemistry.

RN 596817-67-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(5-nitro-2-pyridinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-68-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(6-chloro-2-pyridinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-69-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(4-methyl-2-pyridinyl)-, (3-exo)- (CA INDEX NAME)

RN 596817-70-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(5-bromo-2-pyridinyl)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-71-9 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3-exo)-3-amino-8-azabicyclo[3.2.1]oct-8-yl]-6-methyl- (CA INDEX NAME)

Relative stereochemistry.

RN 596817-72-0 CAPLUS

Relative stereochemistry.

- RN 596817-73-1 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(6-chloro-3-pyridazinyl)-, (3-exo)-(CA INDEX NAME)

- RN 596817-74-2 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(4-chloro-2-pyrimidinyl)-, (3-exo)-(CA INDEX NAME)

Relative stereochemistry.

- RN 596817-75-3 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(6-chloropyrazinyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-76-4 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(2-chloro-4-pyrimidinyl)-, (3-exo)-(CA INDEX NAME)

Relative stereochemistry.

RN 596817-77-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(6-chloro-4-pyrimidinyl)-, (3-exo)-(CA INDEX NAME)

Relative stereochemistry.

RN 596817-78-6 CAPLUS

Relative stereochemistry.

RN 596817-79-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[2-(methylthio)-4-pyrimidinyl]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-89-9 CAPLUS
- CN 9-Azabicyclo[3.3.1]nonan-3-amine, 9-pyrazinyl-, (3-exo)- (9CI) (CA INDEX NAME)

- RN 596817-90-2 CAPLUS
- CN 3-Pyridinecarbonitrile, 6-[(3-exo)-3-amino-9-azabicyclo[3.3.1]non-9-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596817-92-4 CAPLUS
- CN 9-Azabicyclo[3.3.1]nonan-3-amine, 9-(2-pyrimidinyl)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

- RN 599165-27-2 CAPLUS
- CN Carbamic acid, [(3-endo)-8-(2-pyrimidiny1)-8-azabicyclo[3.2.1]oct-3-y1]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 599165-28-3 CAPLUS

CN Carbamic acid, [(3-endo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 599165-29-4 CAPLUS

CN Carbamic acid, [(3-endo)-9-(5-cyano-2-pyridiny1)-9-azabicyclo[3.3.1]non-3-y1]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 599165-31-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-(2-pyrimidiny1)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.

RN 599165-32-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-pyrazinyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

<12/04/2007>

Erich Leese

RN 599165-33-0 CAPLUS

Relative stereochemistry.

IT 596816-23-8P 596816-26-1P 596816-27-2P 596816-28-3P 596816-29-4P 596816-30-7P 596816-31-8P 596816-32-9P 596816-33-0P

596816-34-1P 596816-35-2P 596816-36-3P 596816-37-4P 596816-38-5P 596816-39-6P 596816-40-9P 596816-41-0P 596816-51-2P


596816-52-3P 596816-53-4P 596816-56-7P 596818-14-3P 599165-24-9P 599165-25-0P 599165-36-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoacetylpyrrolidinecarbonitriles as inhibitors of DPP-IV) RN 596816-23-8 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 4-fluoro-1-[[[(3-exo)-8-pyraziny1-8-azabicyclo[3.2.1]oct-3-y1]amino]acetyl]-, dihydrochloride, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HC1

RN 596816-26-1 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-8-(2-pyridiny1)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

RN 596816-27-2 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

● 2 HCl

RN 596816-28-3 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(5-cyano-2-pyridiny1)-8azabicyclo[3.2.1]oct-3-y1]amino]acetyl]-4, 4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

● 2 HC1

- RN 596816-29-4 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-8-(5-nitro-2pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596816-30-7 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(6-chloro-2-pyridiny1)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4,4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

- RN 596816-31-8 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-8-(4-methy1-2-

pyridinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●3 HC1

- RN 596816-32-9 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(5-bromo-2-pyridinyl)-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4,4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

● 2 HC1

- RN 596816-33-0 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[(3-exo)-8-(3-cyano-6-methyl-2-pyridinyl)-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4,4-difluoro-, dihydrochloride (9C1) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

- RN 596816-34-1 CAPLUS
- CN 3-Pyridazinecarbonitrile, 6-[(3-exo)-3-[[2-(2-cyano-4,4-difluoro-1-pyrrolidinyl)-2-oxoethyl]amino]-8-azabicyclo[3.2.1]oct-8-yl]- (CA INDEX NAME)

Relative stereochemistry.

- RN 596816-35-2 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(6-chloro-3-pyridaziny1)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4,4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

- RN 596816-36-3 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(4-chloro-2-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4,4-difluoro-, dihydrochloride

(9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

- RN 596816-37-4 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(6-chloropyraziny1)-8azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4,4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

- RN 596816-38-5 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[(3-exo)-8-(2-chloro-4-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4, 4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

RN 596816-39-6 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(6-chloro-4-pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4, 4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

RN 596816-40-9 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-8-(5-cyanopyraziny1)-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-4,4-difluoro-, hydrochloride (2:3) (9CI) (CA INDEX NAME)

Relative stereochemistry.

●3/2 HC1

- RN 596816-41-0 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-8-[2-(methylthio)-4-pyrimidinyl]-8-azabioyclo[3.2.1]oct-3-yl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

- RN 596816-51-2 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-endo)-8-(2-pyrimidiny1)-8azabicyclo[3.2.1]oct-3-y1]amino]acety1]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596816-52-3 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-9-pyraziny1-9-azabicyclo[3.3.1]non-3-y1]amino]acety1]-, dihydrochloride (9CI) (CA INDEX

NAME)

Relative stereochemistry.

●2 HC1

RN 596816-53-4 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-exo)-9-(5-cyano-2-pyridinyl)-9-azabicyclo[3.3.1]non-3-yl]amino]acetyl]-4, 4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

RN 596816-56-7 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-endo)-9-(2-pyrimidiny1)-9-azabicyclo[3.3.1]non-3-yl]amino]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- RN 596818-14-3 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4-fluoro-1-[[[(3-exo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

- RN 599165-24-9 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-endo)-8-pyrazinyl-8-azabicyclo[3.2.1]oct-3-yl]amino]acetyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●3 HCl

- RN 599165-25-0 CAPLUS
- CN 2-Pyrrolidinecarbonitrile, 1-[[[(3-endo)-9-(5-cyano-2-pyridiny1)-9-azabicyclo[3.3.1]non-3-y1]amino]acety1]-4,4-difluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

●2 HC1

RN 599165-36-3 CAPLUS
CN 2-Pyrrolidinecarbonitrile, 4,4-difluoro-1-[[[(3-exo)-8-(2-pyrimidiny1)-8azabicyclo[3.2.1]oct-3-y1]amino]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:964330 CAPLUS

DOCUMENT NUMBER: 138:39295

TITLE: Preparation of heterocyclic compounds as Rho-kinase

inhibitors

INVENTOR(S): Imazaki, Naonori; Kitano, Masafumi; Ohashi, Naohito;

Matsui, Kazuki

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan

SOURCE: PCT Int. Appl., 425 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

		TENT :				KIN		DATE								D.	ATE	
	WO 2002100833							WO 2002-JP5609										
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KR,	KZ,	LC,	LK,	LR,	LS,
			LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	ΝZ,	OM,	PH,	PL,
			PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,
			UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW								
		RW:	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	BE,	CH,
			CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,
								CM,										
	AU 2002306284				A1 20021223			AU 2002-306284										
	EΡ	1403	255			A1		2004	0331		EP 2	002-	7333	52		2	0020	606
		R:						ES,					LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	LV,	FΙ,	RO,	MK,	CY,	AL,	TR						
		2004									US 2	003-	4805	26		2	0031	212
		7199						2007	0403									
PRIOR	RIT	Y APP	LN.	INFO	. :							001-						
												001-					0011	
											WO 2	002-	JP56	09	1	W 2	0020	606
OTHER	R S(DURCE	(S):			MAR	PAT	138:	3929!	5								

F

AB The title compds. I (wherein one to four groups represented by the general formula R1-X are present and may be the same or different from each other; A is a saturated or unsatd. five-membered heterocycle; X is a single bond, N(R3), O, S, or the like; R1 is hydrogen, halogeno, nitro, carboxyl, substituted or unsubstituted alkyl, or the like; R2 is hydrogen, halogeno, nitro, carboxyl, substituted or unsubstituted alkyl, or the like; and R3 is hydrogen, substituted or unsubstituted alkyl, or the like] are prepared N-(1-Benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride monohydrate in vitro showed 1C50 of 0.4 µL/mL against Rho-kinase.

IT 478837-97-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as Rho-kinase inhibitors)

RN 478837-97-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-cyclohexyl-N-1H-indazol-5-yl- (CA INDEX NAME)

REFERENCE COUNT:

54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 9 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:827020 CAPLUS

DOCUMENT NUMBER: 136:294764

TITLE: Synthesis of 2-(2,3-dimethoxyphenyl)-4-

(aminomethyl)imidazole analogues and their binding affinities for dopamine D2 and D3 receptors

AUTHOR(S): Huang, Yunsheng; Luedtke, Robert R.; Freeman, Rebekah

A.; Wu, Li; Mach, Robert H.

CORPORATE SOURCE: Department of Radiology-PET Center, Wake Forest University School of Medicine, Winston-Salem, NC,

27157, USA

SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(12), 3113-3122

CODEN: BMECEP; ISSN: 0968-0896 PUBLISHER . Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:294764

A series of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole derivs. was prepared and their affinity for dopamine D2 and D3 receptors was measured using in vitro binding assays. Several oxadiazole analogs were also prepared and tested for their affinity for dopamine D2 and D3 receptors. The results of receptor binding studies indicated that the incorporation of an imidazole moiety between the Ph ring and the basic nitrogen did not significantly increase the selectivity for dopamine D3 receptors, whereas the incorporation of an oxadiazole at the same region resulted in a total loss of affinity for both dopamine receptor subtype binding sites. The most selective compound in this series is 6,7-dimethoxy-2-[[2-(2,3dimethoxyphenyl)-1H-imidazol-4-yl]methyl]-1,2,3,4-tetrahydroisoquinoline, which has a D3 receptor affinity of 21 nM and a 7-fold selectivity for D3 vs. D2 receptors. The binding affinity for σ1 and σ2 receptors was also measured, and the results showed that several analogs were selective ol receptor ligands.

407610-27-9P 407610-28-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and dopamine D2 and D3 receptor affinity of

2-(2,3-dimethoxyphenyl)-1H-imidazole-4-methanamine derivs.) 407610-27-9 CAPLUS

RN

CN 9-Azabicyclo[3.3.1]nonan-3-amine, N-[[2-(2.3-dimethoxyphenyl)-1H-imidazol-4-vllmethvll-9-phenvl- (9CI) (CA INDEX NAME)

RN 407610-28-0 CAPLUS

9-Azabicyclo[3.3.1]nonan-3-amine, N-[[2-(5-bromo-2,3-dimethoxyphenyl)-1H-CN imidazol-4-yl]methyl]-9-phenyl- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 10 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:
                        2001:229244 CAPLUS
DOCUMENT NUMBER:
                         135:13871
TITLE:
                        Synthesis and structure-activity relationships of
                        naphthamides as dopamine D3 receptor ligands
AUTHOR(S):
                        Huang, Yunsheng; Luedtke, Robert R.; Freeman, Rebekah
                        A.; Wu, Li; Mach, Robert H.
CORPORATE SOURCE:
                        Department of Radiology-PET Center and Department of
                        Physiology Pharmacology, Wake Forest University School
                        of Medicine, Winston-Salem, NC, 27157, USA
SOURCE:
                        Journal of Medicinal Chemistry (2001), 44(11),
                        1815-1826
                        CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:
                        American Chemical Society
DOCUMENT TYPE:
                        Journal
LANGUAGE:
                        English
OTHER SOURCE(S):
                        CASREACT 135:13871
```

A series of naphthamides were synthesized, and the affinities of these compds. were determined for dopamine D2 and D3 receptors using radioligand binding techniques. The naphthamide compds. that were prepared include N-(1-alkylpiperidin-4-yl)-4-bromo-1-methoxy-2-naphthamides (1-6), (S)-N-(1-alkylpyrrolidin-3-y1)-4-bromo-1-methoxy-2-naphthamides (7-12), (R)-N-(1-alkylpyrrolidin-3-yl)-4-bromo-1-methoxy-2-naphthamides (13-18), (S)-N-(1-alky1-2-pyrrolidiny1methy1)-4-bromo-1-methoxy-2-naphthamides (19-25), (R)-N-(1-alkyl-2-pyrrolidinylmethyl)-4-bromo-1-methoxy-2naphthamides (26-31), and N-(9-alkyl-9-azabicyclo[3.3.1]nonan-3β-yl)-4-bromo-1-methoxy-2-naphthamides (32, 33). The results of in vitro radioligand binding studies indicated that the majority of the naphthamide analogs bound with high affinity at both the D2 and D3 dopamine receptor subtypes and most of the compds. demonstrated some selectivity for the dopamine D3 dopamine receptor subtype. These results demonstrated that both the structure of the central amine moiety (piperidine, pyrrolidine, and 9-azabicyclo[3.3.1]nonane) ring and the N-(alkyl) substitution on the amine significantly effects the binding affinity at D2 and D3 dopamine receptors. The bulkiness of the N-(1-alkyl) substituent was found to (a) have no effect on pharmacol. selectivity, (b) increase the affinity at D3 receptors, or (c) decrease the affinity at D2 receptors. The most potent analog in this series was (S)-N-(1-cycloheptylpyrrolidin-3-yl)-4-bromo-1methoxy-2-naphthamide (10), which had equilibrium dissociation (Ki) values of

1 8 and 0.2 nM for D2 and D3 receptors, resp. The most selective analog was (R)-N-(1-cyclohepty1-2-pyrrolidiny1methy1)-4-bromo-1-methoxy-2-naphthamide (30), which had Ki values of 62.8 and 2.4 nM for D2 and D3 receptors, resp. Radioligand binding results for o receptors indicated that the structure of the amine moiety and the N-(1-alkyl) substitutions also significantly influence the affinity and selectivity of these compds. at the ol and o2 sigma receptor subtypes. The two naphthamides containing a 9-azabicyclo[3.3.1]nonan-3β-yl central ring were found to be selective for 62 receptors.

342876-79-3P RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


(design and SAR of naphthamides as dopamine D3 receptor ligands) 342876-79-3 CAPLUS

RN

2-Naphthalenecarboxamide, 4-bromo-N-[(3-exo)-9-cyclohexyl-9-

azabicyclo[3.3.1]non-3-y1]-1-methoxy- (CA INDEX NAME)

Relative stereochemistry.



IT 342876-83-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(design and SAR of naphthamides as dopamine D3 receptor ligands)

RN 342876-83-9 CAPLUS

CN 9-Azabicyclo[3.3.1]nonan-3-amine, 9-cyclohexyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.

REFERENCE COUNT:

44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:101950 CAPLUS

DOCUMENT NUMBER: 118:101950

TITLE: Preparation of pyrazolo[1,5-a]pyridine derivatives as

serotonin 3 (5-HT3) antagonists

INVENTOR(S): Ito, Yasuo; Kato, Hideo; Yasuda, Shingo; Iwasaki,

Nobuhiko; Nishino, Hirovuki

PATENT ASSIGNEE(S): Hokuriku Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04257591	A	19920911	JP 1991-37776	19910208
PRIORITY APPLN. INFO.:			JP 1991-37776	19910208
OTHER SOURCE(S):	MARPAT	118:101950		

PR

- The title derivs. I (R1 = H, lower alkyl; R2 = H, PhCH2, lower alkyl; X = AB NH, O; n = 2, 3) or their pharmaceutically acceptable salts are prepared as 5-HT3 antagonists (no data). Chlorination of 1.00 g pyrazolo[1,5a]pyridine-3-carboxylic acid in CH2Cl2 gave pyrazolo[1,5-a]pyridine-3carbonyl chloride, which in CH2C12 was added dropwise into a mixture of 0.95 g exo-8-methyl-8-azabicyclo[3.3.1]octan-3-amine and Et3N in CH2Cl2 under ice cooling, then stirred at room temperature for 1.5 h to give 0.88 g exo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)pyrazolo[1,5-a]pyridine-3carboxamide.
 - 145663-01-0P
 - RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as 5-HT3 antagonist)

Ι

- RN 145663-01-0 CAPLUS
- CN Pyrazolo[1,5-a]pyridine-3-carboxamide, N-(9-phenyl-9-azabicyclo[3.3.1]non-3-v1)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.

ANSWER 12 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:510862 CAPLUS DOCUMENT NUMBER: 101 - 110862

ORIGINAL REFERENCE NO.: 101:16933a, 16936a

Studies on the neuroleptic benzamides. III. TITLE:

Synthesis and antidopaminergic properties of new

3-nortropane derivatives

Dostert, Philippe; Imbert, Thierry; Langlois, Michel; AUTHOR(S):

Bucher, Bernard; Mocquet, Gisele CORPORATE SOURCE:

Cent. Rech., Rueil-Malmaison, 92500, Fr.

SOURCE: European Journal of Medicinal Chemistry (1984), 19(2), 105-10

CODEN: EJMCA5; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE . English

OTHER SOURCE(S): CASREACT 101:110862

GI

- AR Pyrimidinecarboxamides were prepared from 4-alkoxypyrimidine-5-carboxylic acids and 3-aminonortropane derivs, and were tested for their potential antipsychotic activity. I (R = H, Me) had pharmacol. activity equivalent to that of haloperidol but had lower toxicity and lower potency to induce catalepsy. Some aspects of structure-activity relationships are discussed.
- ΙT 76272-54-3
 - RL: RCT (Reactant); RACT (Reactant or reagent)
- (acylation of, with aminomethoxypyrimidinecarboxylic acid)
- RN 76272-54-3 CAPLUS
- CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-cyclohexyl-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- 91595-99-2P
 - RL: SPN (Synthetic preparation); PREP (Preparation) (prepn and antidopaminergic activity of)
- RN 91595-99-2 CAPLUS
- CN 5-Pyrimidinecarboxamide, 2-amino-N-(8-cyclohexyl-8-azabicyclo[3.2.1]oct-3y1)-4-methoxy-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L3 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1981:65477 CAPLUS DOCUMENT NUMBER: 94:65477

ORIGINAL REFERENCE NO.: 94:10669a,10672a

TITLE: Azabicycloalkyl derivatives and pharmaceutical compositions containing them

APPLICATION NO.

DATE

INVENTOR(S): Hadley, Michael Stewart; King, Francis David

PATENT ASSIGNEE(S): Beecham Group Ltd., UK

CODEN: EPXXDW

KIND DATE

SOURCE: Eur. Pat. Appl., 63 pp.

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO.

PA	TENT NO.			VIM		DATE	AP	PLICATION NO.		DAIL
	13138			A1		19800709 19831207	EP	1979-302978		19791220
EP						GB, IT,		-		
ED	81054	DE,	Cn,	7.2	rr,	10030615	ML, S	1982-109116		10701220
	01054			7.2		19830824	EP	1902-109110		19/91220
						19861217				
LIE						GB, IT,		·F		
AT	24320	DD,	C11,	т,	111,	19870115	AT	1982-109116		19791220
ED	220339			Δ1		19870506	EP	1982-109116 1985-115575		19791220
EP	220339			B1		19891108		1505 115575		13/31220
	R. BE	CH.	DE.	FR.	GB	TT. NI.	SE			
DK	7905539	,	,	A	,	19800815 19800712 19810616 19800703 19830324	DK	1979-5539		19791221
JP	55092384			A		19800712	JP	1979-170199		19791226
US	4273778			A		19810616	US	1979-107413		19791226
AU	7954255			A		19800703	AU	1979-54255		19791228
AU	527837			B2		19830324				
ES	487379			A1		19801201	ES	1979-487379 1979-7054 1979-342845 1980-200768 1981-271990		19791228
ZA	7907054			A		19801231	ZA	1979-7054		19791228
	1218062			A1		19870217	CA	1979-342845		19791231
	4336259			A		19820622	US	1980-200768		19801027
	4544660			A		19851001	US	1981-271990		19810609
	4599420			A A2		19860708	US	1302-403001		19030223
	1220473			A2		19870414	CA	1984-446870		19840206
	4705858			A		19871110	US	1986-824458		19860131
	02072178					19900312		1989-112779		19890501
	03075548			В		19911202				
PRIORIT	Y APPLN.	INFO	.:					1978-50380		
								1979-9262		
								1979-27831		19790809
								1979-302978		19791220
								1982-109116		
								1979-107413		
								1979-342845		
								1981-271990 1983-469681		
							US	1983-469681	A.3	19830225

OTHER SOURCE(S): MARPAT 94:65477

GI

$$\begin{array}{c|c}
R^2 & (CH_2)_q & (CH_2)_p \\
R^1 & R
\end{array}$$

Azabicycloalkanes I (R = alkoxy; R1, R2 = H, halogen, CF3, acyl, acylamino, NH2, optionally substituted CONH2, SO2NH2, alkylsulfonyl, NO2; R3 = H, alkyl; R4 = optionally substituted alkyl; n, p, q = 0-2) were prepared Thus I [R = OMe, R1 = 4-NHAc (II), R2 = 5-C1, R3 = H, R4 = CH2Ph,n = p = 0, q = 1] was obtained as a mixture of 3' α - and 3'β-isomers by acylating 3-amino-8-benzylnortropane (III) and was deacylated to II (R1 = 4-NH2). III was obtained by LiAlH4 reduction of 8-benzyl-3-nortropanone oxime. II (R1 = 4-NH2) inhibited apomorphine-induced stereotype behavior at ≤10 mg/kg s.c. in rats and was antiemetic at 0.0025 mg/kg s.c. in dogs.

Т

- 76272-92-9P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 - (preparation and deacetylation of)
- 76272-92-9 CAPLUS
 Benzamide, 4-(acetylamino)-5-chloro-N-(8-cyclohexyl-8-azabicyclo[3.2.1]oct-CN 3-v1)-2-methoxv-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.

- 76272-91-8P
 - RL: SPN (Synthetic preparation); PREP (Preparation)
- (preparation and dopamine antagonist and antiemetic activity of) RN 76272-91-8 CAPLUS
- CN Benzamide, 4-amino-5-chloro-N-(8-cyclohexyl-8-azabicyclo[3.2.1]oct-3-yl)-2methoxy-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.

IT 76272-54-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, with methoxybenzoyl chloride derivative)

RN 76272-54-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-cyclohexyl-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L3 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1961:82268 CAPLUS

DOCUMENT NUMBER: 55:82268

ORIGINAL REFERENCE NO.: 55:15609d-e

TITLE: State of transforming deoxyribonucleic acid (DNA) during the first phase of bacterial transformation

AUTHOR(S): Taylor, Harriett Ephrussi

CORPORATE SOURCE: Lab. genetique physiol., Gif-sur-Yvette, Fr.

SOURCE: Comptes Rendus des Seances de la Societe de Biologie

et de Ses Filiales (1960), 154, 1951-5

CODEN: CRSBAW; ISSN: 0037-9026 DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

Expts. with pneumococci seemed to indicate that at the stage of fixation of added transforming DNA the latter is firmly bound to a protein of the receptor cell, and that it retains its high mol. weight until liberation

within the cell by growth processes. 123935-68-2P, Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3-

nortropanyl)-2-thio-RL: PREP (Preparation)

(preparation of)

RN 123935-68-2 CAPLUS

CN Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3-nortropanyl)-2-thio-(6CI) (CA INDEX NAME)

L3 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1961:82267 CAPLUS DOCUMENT NUMBER: 55:82267

ORIGINAL REFERENCE NO.: 55:15609c-d

Action of lysozyme on Haemophilus pertussis

AUTHOR(S): Dumazert, C.; Ghiglione, C.

SOURCE: Bulletin de la Societe de Pharmacie de Marseille (1960), 9, 145-59, 161-71

CODEN: BSPMAC: ISSN: 0560-5237

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

Action of lysozyme on bacterial suspensions of H. pertussis resulted in the isolation of a glucoside fraction and a protein fraction. The glucoside contains glucose, galactose, and an unidentified N base. The protein has not been fully characterized. Immunological studies on the glucoside fraction indicate properties similar to a hapten isolated from Pneumococcus.

IT 123935-68-2P, Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3nortropany1)-2-thio-

RL: PREP (Preparation) (preparation of)

RN 123935-68-2 CAPLUS

CN Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3-nortropanyl)-2-thio-(6CI) (CA INDEX NAME)

L3 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 1959:2191 CAPLUS DOCUMENT NUMBER: 53:2191 ORIGINAL REFERENCE NO.: 53:430h-i,431a-i,432a-i TITLE: Tertiary amino substituted 1,5-iminocycloalkanes INVENTOR(S): Archer, Sydney PATENT ASSIGNEE(S): Sterling Drug Inc. DOCUMENT TYPE: Patent LANGUAGE: Unavailable FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: ATENT NO. KIND DATE APPLICATION NO. DATE

SS 2845427 19580729 US 1955-483808 19550124 PATENT NO. HS 2845427 N-Substituted 1,5-iminocycloalkanes (I) attached at the 3-position through an O, S, or N atom to a tertiary amino alkyl group, which are useful for the reduction of hypertension (the salts and quaternary derivs. are even more active), are prepared by treating a 3-oxo derivative of I with a tertiary amino alkylamine and reducing the resulting imine by condensing the 3-alkali metal sulfide or oxide derivative of I with a tertiary amino alkyl halide and (or) by condensing 3-halo derivative of I with the alkali metal salt of a tertiary amino alkyl mercaptan or hydroxide. 3-Tropolone (30 g.), 24 g. Et2N(CH2)2NH2, 1.2 g. Pt02, and 50 ml. EtOH was shaken 1 hr. under 50 lb. H, filtered, and the filtrate distilled to give 33.2 g. 3-(2-diethylaminoethylamino)-tropane (II), b0.5 111-15°; tri-HCl salt, m. 267-71°; picrate, m. 163.5-6°; dimethiodide, m. 269°; dimethobromide, m. 289-90°. II (59 g.) was cooled to solid CO2 temperature, 54 ml. 100% HCO2H and 24.6 ml. 36% H2CO added, the mixture heated on the steam bath 16 hrs., cooled and made basic, extracted with Et20, and the product distilled to vield 42.5 g. 3-[(2diethylaminoethyl)methylamino]tropane, b0.8-1 120-3°, n25D 1.4871; tri-HBr salt, m. above 140°; dimethiodide, m. 242-4°; dimethobromide, m. 245-7°; diethiodide, m. 237-8°. Similarly the following 3-substituted derivs. of tropane were prepared (side chain, b.p./mm., and salts with their m.p. given): Me2N(CH2)2NH, 101.5-3°/0.5 (n25D 1.4880); Me2N(CH2)2NMe, 104-7°/1.2 (n25D 1.4900-9), di-MeI 238-41°; C5H10N(CH2)3NH, 141-50°/0.5; C5H10N(CH2)3NMe, 141-8°/0.2 (n25D 1.5057), di-MeI 222-3°, tri-MeI 207-14°; C5H10N(CH2)2NH, 132-3°/0.5, tri-HC1 275-7°, di-MeI 293°; C5H10N(CH2)2NMe, 118.5-26°/0.07, tri-HBr 220-4.5°, di-MeI 259-66°, di-EtI 215-19°; C4H4N(CH2)3NH, 140-4°/0.05; C4H4N(CH2)3NMe, 129-31°/0.2 (n25D 1.5031-40), di-MeI 226-8°; C4H4N(CH2)2NH, 130-5°/0.5, di-MeI 290-3°; C4H4N(CH2)2NMe, 122-4°/0.3 (n25D 1.5055-60), di-MeI 205-20°; C4H4N(CH2)4NH, 142-8°/0.3 (n25D 1.5038-41); C4H4N(CH2)4NMe, 138-41°/0.2 (n52D 1.5029); OC4H8N(CH2)2NH, 133-5°/0.4 (n25D 1.5066), tri-HCl 245-9.5°, di-MeI 264-5°; OC4H8N(CH2)2NMe, 124-30°/0.1 (n25D 1.5079-83), tri-HBr 252-4°, di-MeI 218-20°; Me2N(CH2)3NH, 112-14°/1.7 (n25D 1.4990), picrate

<12/04/2007> Erich Leese

230°, Mc2M(CH2)3MMe, 106-12°/0.5 (n25D 1.4885-8), picrate 231°; Et2N(CH2)3MH, 120-5°/0.1 (n25D 1.4862); Et2N(CH2)3MMe, 120-30/0.1 (n25D 1.4870), di-Me1 222-7°; PhMeN(CH2)2MH (III), 167-73°/0.1; PhEtN(CH2)2MH (IV), 174-7°/0.6, MeI 226-8°; p-MeC6H4MMe (CH2)2MH, 164-73°/0.3 (n23.5D 1.5532);

```
p-MeOC6H4NMe(CH2)2NH, 179-83°/0.5 (n24D 1.5560); NH(CH2)2NH (bis
compound), 178-81°/0.6; and NMe(CH2)2NMe (bis compound),
192-200°/1.5, di-MeI 273-4°. II (3.8 g.) and 2.2 g. PhNCS
heated in MeOH gave 3.7 g. 1-(2-diethylaminoethyl)-1-(3-tropanyl)-3-
phenylthiourea (V), m. 170.5-2°. The following derivs. of II were
prepared (group replacing the H of the secondary amine, b.p./mm., or m.p.,
and certain salts with their m.p. given): MeCH:CHNHCS, 97-100°;
EtNHCS, 122-4°; 4-EtOC6H4NHCS, 160-1°; Ac (VI),
142-4°/0.09 (n25D 1.4980), picrate 198-200°; EtCO (VII),
160°/0.5 (n25D 1.4940-5), picrate 173-6°; and PrCO (VIII),
162-6°/0.7 (n28D 1.4935), picrate 194-6°. VI, VII, and VIII
were reduced with LiAlH4 in Et20 to the following N-substituted derivs. of
II (substituent, b.p./mm., n28D, and salts given): Et, 142°/2,
1.4845, di-MeI 230-1°, di-EtI 226°; Pr, 119-26°/0.1,
1.4835, picrate 223°, di-MeI 203-9°; and Bu,
125-30°/0.1, 1.4839, picrate 208-10°. Other 3-substituted
tropane derivs. that were prepared are (side chain, b.p. m/m., and salts
given): C4H4N(CH2)2N(CHO), 166-72°/0.9 (n24D 1.5131);
PhEtN(CH2)2N(CHO), 200-7°/0.1-0.2; PhEtN(CH2)2NMe, 182-7°/15
(n24D 1.5518), di MeI 240-2°; p-MeC6H4NMe(CH2)2N(CHO),
95-7°; p - MeC6H4NMe(CH2)2NMe, 174-6°/0.5 (n24D 1.5508-10),
HCl 168°, tri-MeI 215°; p-MeOC6H4NMe(CH2)2N(CHO),
112-14°; p-MeOC6H4NMe(CH2)2NMe (IX), 162-6°/0.1 (n25D
1.5518), picrate 205-7°, di-MeI 195-8°. Formic acid (26.5
ml.), 500 ml. H2O, and 29 g. III followed by 10 ml. 37% H2CO was heated
15 hrs. on the steam bath to give 1-methyl-4-(3-tropanyl)-1,2,4,5-
tetrahydro-1, 4-benzodiazepine (X), b0.6 155-65°; di-MeI salt (XI),
m. 264-7°; di-EtI salt, m. 208-10°. X was methylated in the
7-position with H2CO and HCO2H, b0.2 163°; picrate, m.
230-1°; methiodide, m. 274-6°. XI subjected to a Hofmann
degradation gave 1-[(2-dimethylaminobenzyl)vinylamino]-3-dimethylamino-5-
cycloheptene; dipicrate, m. 193-4°. IV, H2CO, and HCO2H gave the
1-Et homolog of X, b0.5 174-8° (di-MeI salt, m. 269-71°; MeI
salt, m. 235-8°; di-MeBr salt, m. 262-2.5°; di-EtBr salt, m.
253-4°), and IX under these conditions gave the 7-methoxy derivative of
X, b0.1 180-5°; picrate, m. 239-40°. III heated with 98%
HCO2H gave 3-[2-(phenylmethylaminoethyl)formylamino]tropane, b0.5
216-22°, which was reduced with LiAlH4 to the N-Me derivative, b0.6
160-5°; dimethiodide, m. 255°; dimethobromide, m.
258°. Tropine (60 g.) in 50 ml. MePh was added to 9.2 g. Na in 100
ml. MePh, the mixture refluxed 4 hrs. and 42.8 g. Me2N(CH2)2Cl added, the
mixture refluxed 3 hrs., aqueous MeOH added, and distilled to give 17.3 g.
3-(2-dimethylaminoethoxy)tropane, b0.9 85-5.5°, n25D 1.4836;
diperchlorate, m. 243-6°; dimethiodide, m. 314-15°;
diethiodide, m. 269-75°. Similarly, the following 3-substituted
tropanes were prepared (side chain, b.p./mm., and salts and their m.p.
given): Et2N(CH2)20, 101°/0.07 (n25D 1.4758), di-MeI 301-2°;
C5H10N(CH2)2O, 106-9°/0.07, di-MeI 305°; C5H10N(CH2)3O, 115°/0.1, di-MeI above 305°; C4H4N(CH2)2O, 134°/2.8
(n25D 1.4932), di-MeI 313-14°; Et2N(CH2)30(CH2)30,
94-6°/0.2, di-MeI 300°. Pseudotropine, Na, and Et2(CH2)2C1
in C6H6 gave 3-(2-diethylaminoethoxy)pseudotropane, b0.25, 109-12°,
n25D 1.4775; dimethiodide, m. 307-8°. Tropanone (69.5 g.), 63.8 g.
Et2N(CH2)2NH2, and 500 mg. ZnCl2 in MePh was heated 64 hrs. using an H2O
separator to yield 92.2 g. 3-(2-diethylaminoethylimino)tropane (XII), b0.6
117-31°. XII was reduced by Na and EtOH to a mixture of
3-(2-diethylaminoethylamino)tropane and pseudotropane. The mixture of
```

```
isomers and PhNCS gave V and the isomeric pseudotropane, m.
138-9.5°. By this procedure pseudopelletierine (XIII) and
C5H10N(CH2)2NH2 yielded 3-[2-(1-piperidyl)ethylimino]-9-methylgranatanine,
bl 164-76°, n25D 1.5235, which was reduced by Na in Me2CH(CH2)3OH
to a mixture of isomers of the corresponding amine which was treated with
PhNCS in MeOH to yield a mixture of isomers of the thiourea (XIV), m.
174.5-6°, (XV) m. 173-4.5° (AcOEt). XIV (7.3 g.), MeOH, and
25 ml. 4N HCl in EtOH was evaporated, the residue heated 30 min. at
100°, dissolved in EtOH, and the solution cooled to yield
3-[2-(1-piperidyl)ethylamino]-9-methylgranatanine; tri-HCl salt (XVI), m.
285-7°. XV treated in this manner gave an isomer of XVI, m.
276°. Similarly, XIII with the appropriate amine gave the
following 3-substituted derivs. of 9-methylgranatanine (side chain,
b.p./mm., and salts with their m.p. given; when isomers were obtained,
both m.p.'s given): C4H4N(CH2)2NH, 144-6°/1 (n24D 1.5252);
C4H4N(CH2)2NH, 155-7°/2 (n25D 1.5102), di-MeI 278°;
C4H4N(CH2)2(PhNHCS)N, 173-4°; Et2N(CH2)2NH, 131-9°/0.7 (n25D
1.5050); Et2N(CH2)2NH, 128-30°/0.6 (n25D 1.4920), tri-HCl
278° and 185°, di-MeI 277-9°; Et2N(CH2)2(PhNHCS)N,
189-91° and 135-6°. Concentrated HCl (0.13 ml.) was added to 160
g. 2.5-diethoxytetrahydrofuran in 150 ml. H2O, the suspension stirred 2
hrs. at 48-50° and cooled, 202 g. (EtO2CCH2)2CO, 100 ml. H2O, 107
q. PhCH2NH2, and 83 ml. HCl added, the mixture stirred overnight, 250 ml.
HCl added, heated while 270 ml. H2O was distilled, the residue filtered, the
filtrate made basic with NaOH, 500 q. K2CO3 added, and the mixture extracted
with Et20 to yield 102 g. 8-benzyltropanone (XVII), b0.4 134-7°,
n25D 1.5526. XVII yielded 3-(2-diethylaminoethylamino)-8-
benzylnortropane, b0.25 161-8°, n25D 1.5235; tri-HCl salt, m.
264-6°; dimethiodide, m. 255-7°; phenylthiourea derivative, m.
138-9°. The following 8-benzylnortropane derivs. are described
(side chain and phenyl substituents, b.p./mm. or m.p., and salts given):
4'-MeO, 3-oxo, 179-84°/0.1 (n25D 1.5538), HCl 203-4°;
4'-MeO, 3-Et2N(CH2)2HN, tri-HCl 277-8°, di-MeI 229-30°;
2',3'-di-MeO, 3-oxo, 178-99°/0.5, HCl 201-2°; 2'-3'-di-MeO,
3-Et2N(CH2)2HN, tri-HCl 234-7°, di-MeI 226-8°; 3,'4'-OCH2O,
3-oxo, tri-HCl 223-3.5°;3',4'-OCH2O,3-Et2N(CH2)2HN, tri-HCl
275-6°, di-MeI 234-7°; 3',4'-OCH2O 3-Et2N(CH2)2(PhNHCS)N,
148-9°; 4'-C1, 3-oxo, 168-80°/0.8; 4'-C1, 3-Et2N(CH2)2HN,
di-MeI 232-4°, di-MeBr 228-30.5°; 2'-Cl,
3-Et2N(CH2)2(PhNHCS)N, 124-6°; 2'-Cl, 3-C4H4N(CH2)2HN, tri-HCl
253°, di-MeI 218-20°; 2'-MeO, 3-oxo, 174-81°/0.2-0.5
(n25D 1.5061-5), HCl 177-8°; 2'-MeO, 3-Et2N(CH2)2HN, tri-HCl
248-51°, di-MeI 218.5-21.5°; 2',4'-di-Cl, 3-oxo,
185-7°/1.5, tri-HCl 216°; and 2,4-di-Cl, 3-Et2N(CH2)2NH,
di-MeI 237-9°. 8-Phenylnortropanone, m. 107-9°, was prepared
by the method used for XIII and reaction with Et2N(CH2)2NH2, Pt02, and H
gave 3-(2-diethylaminoethylamino)-8-phenylnortropane (XVIII), b0.2
153-68°, which with PhNCS gave the thiourea derivative, m.
161-3°, and with Ac20 yielded N-Ac derivative of XVIII, b0.2
183-98°, n25D 1.5470, which was reduced to the N-Et derivative of
XVIII, b0.9 180-4°, n30D 1.5370. PhEtN(CH2)2NH2 (35 g.), 32 g.
XIII, 1 g. ZnCl2, and 200 ml. MePh gave 3-(2-phenylmethylaminoethylaminoet
hylamino)-9-methylgranatanine, b0.2-0.9 160-84°, n30D 1.5575, from
which the following N-substituted derivs. were prepared (b.p./mm. and salts
with their m.p. given): HCO, 190-220°/0.7; Me, 161-6°/0.15,
picrate 191-4°, di-MeI 225-7°; Ac, 200-14°/0.2; and
Et, 162-7°/0.1, picrate 203-5°.
```

- IT 102457-13-6P, Nortropane, 3-[(2-diethylaminoethyl)ethylamino]-8-phenyl- 102463-23-0P, Nortropane, 3-[(2-diethylaminoethyl)methylamino|-8-phenyl- 102709-02-4P, Nortropane, 3-[(2-diethylaminoethyl)amino]-8-phenyl- 110147-72-3P, Nortropane, 3-[N-(2-diethylaminoethyl)acetamidoj-8-phenyl- 123935-68-2P, Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3-nortropanyl)-2-thio- RL: PREP (Preparation)
- (preparation of) RN 102457-13-6 CAPLUS
- CN Nortropane, 3-[(2-diethylaminoethyl)ethylamino]-8-phenyl- (6CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Ph} & & \text{N} & \text{CH}_2\text{--}\text{CH}_2\text{--}\text{NEt}_2 \\ & & \text{Et} & & \end{array}$$

- RN 102463-23-0 CAPLUS
- CN Nortropane, 3-[(2-diethylaminoethyl)methylamino]-8-phenyl- (6CI) (CA INDEX NAME)

- RN 102709-02-4 CAPLUS
- CN Nortropane, 3-[(2-diethylaminoethyl)amino]-8-phenyl- (6CI) (CA INDEX NAME)

- RN 110147-72-3 CAPLUS
- CN Nortropane, 3-[N-(2-diethylaminoethyl)acetamido]-8-phenyl- (6CI) (CA INDEX NAME)

RN 123935-68-2 CAPLUS

<12/04/2007>

CN Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3-nortropanyl)-2-thio-(6CI) (CA INDEX NAME)

ANSWER 17 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1958:6906 CAPLUS DOCUMENT NUMBER: 52:6906

ORIGINAL REFERENCE NO.: 52:1292a-i,1293a-b

3-(Monocarbocyclic aryl-lower alkyl)amino-1,5-TITLE:

iminocycloalkanes INVENTOR(S): Archer, Sydney

PATENT ASSIGNEE(S): Sterling Drug Inc.

DOCUMENT TYPE: Patent LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2798874		19570709	US 1955-502745	19550420

For diagram(s), see printed CA Issue. AB Compds. of the general formula RN.CH.CH2.(CH2)m.CH.CH2.CH(NR'CnH2nAr).CH2 and their salts, where R is lower alkyl, monocarbocyclic aryl, or aryl lower alkyl, R' is H or lower alkyl, m is 1-2, n is 1-6, and Ar is a monocarbocyclic arvl group, are useful in reducing hypertension and exhibit ganglionic blocking action in cats and dogs. They are prepared by reaction of a 3-tropinone (via the Robinson synthesis) and ArCnH2nNH2 under hydrogenation conditions. E.g., 45 g. 3-tropinone (I), 32 g. PhCH2NH2, 1.0 q. PtO2, and 150 ml. EtOH are shaken 4 hrs. at 55° with H at 50 lb. per sq. in. One mole H is taken up. After filtration, the mixture is distilled and redistd, to obtain 34.8 g. 3-benzylaminotropane (II), b0.8 140-2°, n25D 1.5450; picrate, m. 160-1°. II (29.6 g.) is cooled to 20° and 28.2 cc. 98% HCO2H added portionwise

followed by 13 cc. 36% HCHO solution, the mixture warmed to room temperature,

heated 17 hrs. on a steam bath, poured into ice H2O, made basic with 35% NaOH solution, extracted with ether, dried over K2CO3, and distilled to get 21.2 g. 3-(benzylmethylamino)tropane (III), b0.3 135-8°, n25D 1.5416; picrate, m. 230-2° (from HCONMe2); methiodide, m. 233.0-7.5° (decomposition). I (42 g.), 52.5 cc. 5.82N MeNH2 in MeOH, 1.5 g. PtO2, and 100 ml. MeOH treated similarly yield 38.3 g. 3-methylaminotropane (IV), b23 109-10°, n25D 1.4934. When 15.2 q. IV, 12.6 q. PhCH2Cl, and 13.8 g. K2CO3 in 100 cc. PhMe are heated 4 hrs. under reflux and 10% K2CO3 solution then added, three layers are formed. The bottom (aqueous) layer is discarded; the top (PhMe) layer is distilled to dryness, the residue dissolved in ether, filtered, and the filtrate distilled to get 5.6 g. III, b0.8 130-6°. The middle layer is taken up in CHC13, washed with H2O, and the CHCl3 distilled, ether added to an EtOH solution of the residue, and the solid (3.7 g.) separated and recrystd. from EtOH-ether to obtain the 8-benzochloride of III (V), m. 224.0-5.5° (decomposition); 8-(4-nitrobenzobromide) (VI), m. 220-3° (decomposition); 8-(4-chlorobenzochloride) (VII), m. 226-8° (decomposition); 8-(3,4-dichlorobenzochloride) (VIII), m. 232-5° (decomposition); 8-(p-methoxybenzochloride); 8-(p-methylbenzochloride). 3-(4-Chlorobenzylamino)tropane (IX), b0.2 135-53°; picrate, m. 185-7°. 3-(2-Phenylethylamino)-, 3-(3-phenylpropylamino)-, and 3-(2-phenylpropylamino)tropane are prepared by analogous methods. IX is heated with 1 molar equivalent PhNCS to obtain the phenylthiureide, m. 130-2°. Replacement of I in the synthesis of IX with pseudopelletierine gives 3-(4-chlorobenzylamino)-9-methylgranatanine. IX (18.0 g.), 15 ml. 98% HCO2H, and 6.85 ml. 37% HCHO solution yield 12.4 g.

3-[(4-chlorobenzyl)methylamino|tropane (X), b0.3 140°; 8-methiodide (XI), m. 255-6° (decomposition); 8-methobromide, m. 261-3° (decomposition); 8-(4-nitrobenzobromide), m. 210-12° (decomposition). X, b0.1-0.2 144-6°, n25D 1.5483, and its 8-(4-chlorobenzochloride) (XII), m. 202.5-205° (decomposition), are prepared by the method used for III and V. The 8-(3,4-dichlorobenzochloride) of XII, m. 200-3° (decomposition); 8-(2-hydroxyethobromide), m. 219-21°. A mixture of 50 g. 4-Et2NC6H4CH2NH2 and 200 ml. 12% NH3 in MeOH is hydrogenated (Ranev Ni) 3 hrs. at 21-2° at an initial pressure of 890 lbs. per sq. in., filtered, distilled, and redistd. to obtain 23.2 g. 4-diethylaminobenzylamine (XIII), b0.1 122-8°, n25D 1.5592. Hydrogenation of 19.0 g. I, 23.2 g. XIII, and 1 g. PtO2 in 200 ml. absolute EtOH as before, solution of the crude product in absolute EtOH, and addition of excess alc. HCl give 21.5 g. 3-(4-diethylaminobenzylamino)tropane trihydrochloride dihydrate, m. 195° (decomposition); picrate of free base, m. 185° (decomposition). The phenylthiureide m. 145-7°; 8-methiodide (XIV), m. 240-5° (decomposition); 8-(4-chlorobenzochloride) (XV), m. 208-11° (decomposition); 8-(3,4-dichlorobenzochloride), m. 200-3° (decomposition); 8-(4-nitrobenzobromide), m. 189-91°. 3-(Benzylacetylamino)tropane is prepared by treating II with Ac20 followed by hydrolysis; reduction with LiAlH4 yields 3 (benzylethylamino) tropane. A solution of 36.2 g. 2,5-diethoxytetrahydrofuran in 240 cc. H2O containing 0.6 ml. concentrated H2SO4 is warmed 15 min. on a steam bath, cooled, and added to a solution of 97 g.

warmed 15 min. on a steam bath, cooled, and added to a solution of 97 g. CO(CH2CO2H)2, 146 NaOAc.3H2O, and 27 PNNH2 in 3.5 l. H2O. After standing overnight, the solid is collected, dissolved in one 1.5% aqueous HCl at 60°, cooled, made alkaline with NH3, and the product recrystd. from dilute MeOH to obtain 11.4 g. 8-phenylnortropanone (XVI), m. 107-9°, hydrogenation of a mixture of XVI, PhCH2NH2, and PtO2 in EtOH gives 3-benzylamino-8-phenylnortropanone. V, VI, VII, VIII, XII, and XII are 60, 54, 74, 128, 30, and 100% as effective, resp., as hexamethylenebis(trimethylammonium bromide) in blockade of the sympathetic ganglia when measured by the carotid occlusion test in dogs. X, XIV, and XV are similarly 35, 26, and 210% as effective, resp., in cats. 102552-20-5P, Nottropane, 3-benzylamino-8-phenyl-

IT 102552-20-5P, Nortropane, 3-benzylamino-8-phenyl-RL: PREP (Preparation)

(preparation of)

RN 102552-20-5 CAPLUS

CN Nortropane, 3-benzylamino-8-phenyl- (6CI) (CA INDEX NAME)

L3 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1957:86038 CAPLUS

DOCUMENT NUMBER: 51:86038

ORIGINAL REFERENCE NO.: 51:15607c-i,15608a-i,15609a-h
TITLE: Tertiary amino-substituted compounds of the tropane

and granatanine series

PATENT ASSIGNEE(S): Sterling Drug Inc.

DOCUMENT TYPE: Patent LANGUAGE: Unavailable

LANGUAGE: Un FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
PATENT NO. KIND DATE APPLICATION NO.
                                                                    DATE
                                             -----
     GB 762256
                                19561128 GB
AR
     Tertiary amino substituted tropanes, granatanines, and their salts are
     prepared 3-Tropanone (30 g.), 24 g. 2-diethylaminoethylamine, 1.2 g. PtO2,
     and 50 ml. EtOH is shaken in 50 lb./sq. in. H 2.5 hrs., the product
     filtered, the filtrate concentrated, and distilled to give 33.2 g.
     3-(2-diethylaminoethylamino)tropane, b5 111-15°; picrate, m.
     163.5-6° (from aqueous EtOH); trihydrochloride monohydrate, m.
     267-71° (from 95% EtOH, MeOH); bismethiodide, m. 269° (from
     dilute MeOH) (decomposition). To 59 g. 3-[(2-diethylaminoethyl)amino]tropane cooled to -40^{\circ} is added 54 ml. 100% HCO2H followed by 24.6 ml. 36%
     HCHO, the mixture heated to 100° 16 hrs., treated with 35% NaOH,
     extracted with Et20, and then distilled to yield 42.5 g. 3-[(2-
     diethylaminoethyl)methylaminoltropane, b-1.0 120-3°, nD25 1.4871.
     Similarly the following compds. are prepared: 3-[(2-
     diethylaminoethyl)amino]tropane bismethobromide, m. 289-90° (from
     MeOH) (decomposition); 3-[(2-diethylaminoethyl) methylamino]tropane
     trihydrobromide, m. 140° (from MeOH); 3-[(2-
     dimethylaminoethyl)amino|tropane, b0.5 101.5-3°, nD25 1.4880;
     3-[(2-dimethylaminoethyl)methylamino|tropane, b1.2 104-7°, nD25
     1.4900-9, m. 238-41° (decomposition); 3-[3-(1-
     piperidyl)propylamino]tropane, b0.2 141.8-0, nD25 1.5057;
     3-{[3-(1-piperidyl)propyl]methylamino}tropane bisethiodide, m.
     222-33°; 3-{[3-(1-piperidyl)propyl]methylamino}tropane
     trismethiodide, m. 207-14°; 3-[2-(1-piperidy1)ethylamino]tropane,
     b0.5 132-3°; 3-[2-(1-piperidv1)ethylamino|tropane
     trihydrochloride, m. 275-7°; 3-[2-(1-piperidyl)ethylaminoltropane
     bis-methiodide, m. 293°; 3-{[2-(1-piperidyl)ethyl]methylamino}trop
     ane, b0.07 118.5-26°; 3-{[2-(1-piperidyl)ethyl]methylamino}tropane
     trihydrobromide, m. 220-4.5°; 3-{[2-(1-
     piperidyl)ethyl]methylamino}tropane bismethiodide, m. 259-60°;
     3-{[2-(1-piperidvl)ethvl] methvlamino}tropane bisethiodide, m.
     215-19°; 3-[3-(1-pyrrolidyl)propylamino]tropane, b0.05
     140-4°; 3-{[3-(1-pyrrolidyl)propyl]methylamino}tropane, b0.2
     129-31°, nD25 1.5031-40; 3-{[3-(1-pyrrolidyl)propyl]methylamino}tro
     pane bismethiodide, m. 226-8; 3-[2-(1-pyrrolidy1)propy1]methylaminojtto
pyrrolidy1)ethylaminojtropane, b0.5 130-5; 3-[2-(1-
pyrrolidy1)ethylaminojtropane bismethiodide, m. 290-3° (decomposition);
     3-{[2-(1-pyrrolidyl)ethyl]methylamino}tropane, b0.3 122-4°, nD25
     1.5055-60; 3-{[2-(1-pyrrolidyl)ethyl]methylamino}tropane bismethiodide, m.
     205-20°; 3-[4-(1-pyrrolidyl)butylamino]tropane, b0.3
     142-8°, nD25 1.5038-41; 3-{[4-(1-pyrrolidy1)buty1]methylamino}tropa
     ne, b0.2 138-40°, nD25.5 1.5029; 3-[2-(4-
     morpholinylethylamino|tropane, b0.4 133-5°, nD25 1.5066;
```

HC1

```
3-[2-(4-morpholinylethylamino|tropane trihydrochloride, m. 245-9°
     (with decomposition); 3-[2-(4-morpholinyl)ethylaminoltropane bismethiodide, m.
     264.5-5° (decomposition); 3-{[2-(4-morpholiny1)ethy1]methy1amino}tropane
     , b0.1 124-30°, nD25 1.5079-83; 3-{[2-(4-morpholinyl)ethyl]
     methylamino)tropane trihydrobromide, m. 252-4° (decomposition);
     3-{[2-(4-morpholinyl)ethyl]methylamino}tropane bismethiodide, m.
     218-20°; 3-(3-dimethylaminopropylamino) tropane, b1.7
     112-14°, nD24 1.4990 (tripicrate, m. 230°);
     3-[(3-dimethylaminopropyl)methylamino|tropane, b0.5 106-12°, nD26
     1.4885-8 [picrate, m. 231° (decomposition)]; 3-(3-
     diethylaminopropylamino)tropane, b0.1 120-5°, nD25 1.4862
     [picrate, m. 212° (decomposition)]; 3-[(3-diethylaminopropyl)methylamino]
     tropane, b0.1 120-3°, nD25 1.4870; 3-[(3-
     diethylaminopropyl)methylamino]tropane bismethiodide, m. 222-7°.
     Tropine (60 g.), 150 ml. PhMe, and 9.2 g. Na is refluxed 4 hrs., then 3
     more hrs. with 42.8 g. 2-dimethylaminoethyl chloride in 50 ml. PhMe, aqueous
     MeOH added to the cooled product, and the organic layer separated,
concentrated, and
     distilled to yield 17.3 g. 3-(2-diethylaminoethoxy)tropane, b0.9
     85-0.5°, nD25 1.4836; bisperchlorate, m. 243-6° (from aqueous
     AcOH); bismethiodide, m. 314-5° (from MeOH) (decomposition). Similarly,
     the following compds, are prepared: 3-(2-diethylaminoethoxy)tropane, b0.07
     101°, nD25 1.4758; 3-(2-diethylaminoethoxy)tropane bismethiodide,
     m. 301-2° (decomposition); 3-[2-(1-piperidyl)ethoxy|tropane, b0.07
     106-9°; 3-[2-[1-piperidyl)ethoxy|tropane bismethiodide, m. above
     305°; 3-[3-(1-piperidvl)propoxy|tropane, b0.1 115°;
     3-[3-(1-piperidyl)propoxyltropane bismethiodide, m. above 305°;
     3-[2-(1-pyrrolidy1)ethoxy]tropane, b2.8 134°, nD25 1.4932;
     3-[2-(1-pyrrolidyl)ethoxy]tropane bismethiodide, m. 313-4°;
     3-(2-diethylaminoethoxy)pseudotropane, b0.25 109-12°, nD25 1.4775;
     3-(2-diethylaminoethoxy)pseudotropane bismethiodide, m. 307-8°
     (decomposition); 3-(3-diethylaminopropoxy)tropane, b0.2 94-6°;
     3-(3-diethylaminopropoxy)tropane bismethiodide, m. 300° (decomposition).
     3-(2-Diethylaminoethylmercapto)tropane can be prepared by heating
     3-bromotropane with 3-diethylaminoethylmercaptan in NaOH solution
     1-Methyl-4-(3-tropanyl)-1,2,4,5-tetrahydro-1,4-benzodiazepine
     bismethiodide, m. 264-7° (from H2O) (decomposition). Similarly the
     following compds. are prepared: 3-(2-phenylmethylaminoethylamino)tropane,
     b0.1 167-73°; 1-methvl-4-(3-tropanvl)-1,2,4,5-tetrahvdro-1,4-
     benzodiazepine, b0.3 170-2°: 3-(2-phenylethylaminoethylamino)tropan
     e, b0.6 174-7°; 3-(2-phenylethylaminoethylamino)tropane
     8-methiodide, m. 226-8° (decomposition); 1-ethyl-4-(3-tropanyl)-1,2,4,5-
     tetrahydro-1, 4-benzodiazepine, b0.5 174-8°; 1-ethyl-4-(3-tropanyl)-
     1,2,4,5-tetrahydro-1,4-benzodiazepine bismethiodide, m. 269-71°;
     1-ethyl-4-(3-tropanyl)-1,2,4,5-tetrahydro-1,4-benzodiazepine 8-methiodide,
     m. 235-8°; 1-ethyl-4-(3-tropanyl)-1,2,4,5-tetrahydro-1,4-
     benzodiazepine bismethobromide, m. 262-2.5° (decomposition).
     2,5-Diethoxytetrahydrofuran (160 g.), 150 ml. H2O, and 0.13 ml. concentrated
     stirred at 48-50° 2 hrs., cooled to 25°, 202 g. di-Et
     acetonedicarboxylate followed by 100 ml. H2O and 107 g. PhCH2NH2.HCl
```

added, the mixture stirred overnight, treated with 250 ml. HCl, and heated to 103° to remove H2O, the residue filtered off, the filtrate made basic with 250 ml. 35% NaOH, 500 g. K2CO3 added, and extracted 3 times with Et20 gave 102 g. 8-benzylnortropanone, b0.4 134-7, nD25 1.5562. Similarly are prepared: 3-(2-diethylaminoethylamino)-8-benzylnortropane, b0.25

<12/04/2007> Erich Leese

161-8°, nD25 1.5235; 3-(2-diethylaminoethylamino)-8-

```
benzylnortropane trihydrochloride, m. 264-6° (decomposition);
     3-(2-diethylaminoethylamino)-8-benzylnortropane bismethiodide, m.
     255-7°: 3-(2-diethylaminoethylamino)-8-(4-methoxybenzyl)
     nortropane; 3-(2-diethylaminoethylamino)-8-(4-methoxybenzyl)nortropane
     trihydrochloride, m. 277-8° (decomposition); 3-(2-
     diethylaminoethylamino)-8-(4-methoxybenzyl)nortropane bismethiodide, m.
     229-30°; 3-(2-diethylaminoethylamino)-8-(2,3-
     dimethoxybenzyl)nortropane; 3-(2-diethylaminoethylamino)-8-(2,3-
     dimethoxybenzyl)nortropane trihydrochloride, m. 234-7°;
     3-(2-diethylaminoethylamino)-8-(2,3-dimethoxybenzyl)nortropane
     bismethiodide, m. 226-8°; 3-(2-diethylaminoethylamino)-8-(3,4-
     methylenedioxybenzyl) nortropane; 3-(2-diethylaminoethylamino)-8-(3,4-
     methylenedioxybenzyl)nortropane trihydrochloride, m. 275-6°
     (decomposition); 3-(2-diethylaminoethylamino)-8-(3,4-
     methylenedioxybenzyl)tropane bismethiodide, m. 234-7°;
     3-(2-diethylaminoethylamino)-8-(4-chlorobenzyl)nortropane;
     3-(2-diethylaminoethylamino)-8-(4-chlorobenzyl)nortropane
     trihydrochloride, m. 273-5°; 3-(2-diethylaminoethylamino)-8-(2-
     chlorobenzyl)nortropane; 3-(2-diethylaminoethylamino)-8-(2-
     chlorobenzyl)nortropane bismethiodide, m. 232-4°;
     3-(2-diethylaminoethylamino)-8-(2-methoxybenzyl)nortropane
     trihydrochloride, m. 248-51°; 3-(2-diethylaminoethylamino)-8-(2-
     methoxybenzyl)nortropane bismethiodide, m. 218.5-21.5°;
     3-(2-diethylaminoethylamino)-8-phenylnortropane; 3-(2-
     diethylaminoethyl)methylamino-8-phenylnortropane. Hydrated
     pseudopelletierine (29.8 g.), 26 g. 2-(1-piperidyl)ethylamine, 600 mg.
     ZnCl2, and 150 ml. C6H5CH3 refluxed 64 hrs. using a separator to collect
     the H2O formed, the product cooled, washed with 50 ml. saturated K2CO3
solution.
     and the aqueous layer extracted with 4 50-ml. portions of C6H6 yielded 27.8 q.
     3-2-(1-piperidyl)ethylimino-9-methylgranatanine (II), bl 164-76°,
     nD25 1.5235. To 27.8 g. II in 40 g. 4-methyl-2-pentanol is added slowly
     9.2 g. Na in 200 ml. PhMe, the mixture refluxed 0.5 hr., 30 ml. H2O added,
     cooled, the aqueous layer saturated with K2CO3, extracted with 3 100-ml.
portions of
     PhMe, the PhMe layers concentrated, dissolved in 50 ml. MeOH, 15 g. phenyl
     isothiocyanate stirred in, and the precipitate (34.4 g.) filtered off and
     recrystd. from AcOEt. By fractional precipitation from MeOH 2 isomers of 1-2
     (1-piperidvl)ethvl-1-3-(9-methvl)granatanvl-3-phenvlthiourea, isomer A, m.
     174.5-6° (prisms from AcOEt), and isomer B, 173-4.5°
     (needles) are obtained. Also prepared were: 3-[2-(1-piperidyl)ethylamino]-9-
     methylgranatanine trihydrochloride (from isomer A), m. 285-7°
     (decomposition); 3-[2-(1-piperidyl) ethylamino]-9-methylgranatanine
     trihydrochloride (from isomer B), m. 276° (decomposition);
     1-(2-diethylaminoethyl)-1-(3-tropanyl)-3-phenylthiourea, m.
     170.5-2°; 3-(2-diethylaminoethylimino)tropane, b0.6
     117-31°; 3-(2-diethylaminoethylamino)tropane; 1-(2-
     diethylaminoethyl)-1-(3-pseudotropanyl)-3-phenylthiourea, m.
     138-9.5°; 3-(2-diethylaminoethylamino)pseudotropane
     trihydrochloride, m. 276° (decomposition); 3-(2-
     diethylaminoethylamino)pseudotropane bismethiodide, m. 279-81°
     (MeOH); 3-[2-(1-pyrrolidyl)ethylamino]-9-methylgranatanine, b2
     155-7°, nD25 1.5102; 1-[2-(1-pyrrolidyl) ethyl]-1-[3-(9-methyl)
     granatanyl]-3-phenylthiourea, m. 173-4°; 3-[2-(1-
     pyrrolidyl)ethylamino]-9-methylgranatanine bismethiodide, m. 278°
     (decomposition); 3-(2-diethylaminoethylamino)-9-methylgranatanine, b0.6
     128-30°, nD25 1.4920; 1-(2-diethylaminoethyl)-1-(9-
```

```
methylgranatanyl)-3-phenylthiourea, isomer B, m. 188-90°;
     1-(2-diethylaminoethyl)-1-(9-methylgranatanyl)-3-phenylthiourea, isomer A,
    m. 135-6°: 3-(2-diethylaminoethylamino)-9-methylgranatanine
     trihydrochloride, isomer A, m. 278° (decomposition) [trihydrochloride of
     isomer B, m. 185°; bismethiodide of isomer A, m. 277-9°
     (decomposition)];
1-(2-diethylaminoethyl)-1-(3-[8-(2-chlorobenzyl)nortropanyl]}-
     3-phenylthiourea, m. 124-6°; 1-(2-diethylaminoethyl)-1-[3-(8-
     phenyl)nortropanyll-3-phenylthiourea, m. 161-3°.
     3-(2-Diethylaminoethylamino)tropane (4.0 g.) treated with 1.7 ml. allyl
     isothiocyanate yielded 3.6 g. 1-(2-diethylaminoethyl)-1-(3-tropanyl)-3-
     allylthiourea, m. 97-100°. Similarly the following compds. are
     prepared: 1-(2-diethylaminoethyl)-1-(3-tropanyl)-3-ethylthiourea, m.
     122-4°; 1-(2-diethylaminoethyl)-1-(3-tropanyl)-3-(4-
     ethoxyphenyl)thiourea, m. 160-1°; 1-(2-diethylaminoethyl)-1-[3-(8-
     benzyl)nortropanyl]-3-phenylthiourea, m. 138-9°;
     1-(2-diethylaminoethyl)-1-{3[8-(3,4-methylenedioxybenzyl)]nortropanyl}-3-
     phenylthiourea, m. 148-9°; 3-[(2-diethylaminoethyl)acetylamino]tro
     pane, b0.09 142-4°, nD25 1.4980 (picrate, m. 190-200°) (from
     EtOH); 3-[(2-diethylaminoethyl)ethylamino]tropane, b2 142°, nD25
     1.4845 (bismethiodide, m. 230-1°) (decomposition); 3-[(2-
     diethylaminoethyl)ethylamino]tropane bismethiodide, m. 226°
     (decomposition); 3-[(2-diethylaminoethyl)propionylamino]tropane, b0.5
     160°, nD28 1.4940-5 (picrate, m. 173-6°) (from aqueous HCONMe2);
     3-[(2-diethylaminoethyl)propylamino|tropane, b0.1 119-26°, nD28
     1.4835 [picrate, m. 223° (decomposition); bismethiodide, m.
     203-9° (decomposition)]; 3-[(2-diethylaminoethyl)butyrylamino]tropane,
     b0.7 162-6°, nD25 1.4935 (picrate, m. 194-6°);
     3-[(2-diethylaminoethyl)butylamino]tropane, b0.1 125-30°, nD25
     1.4839 [picrate, m. 208-10° (decomposition)]; 3-[(2-
     diethylaminoethyl)acetylamino]-8-phenylnortropane, b0.2 183-98°,
     nD28 1.5470; 3-[(2-diethylaminoethyl)ethylamino]-8-phenylnortropane, b0.9
     180-4°, nD30 1.5370; 3-[(2-phenylethylaminoethyl)formylamino]tropan
     e, b0.1-0.2 200-7°; 3-{[2-(1-pyrrolidyl)ethyl]formylamino}tropane,
     b0.9 166-72°, nD25 1.5131 (picrate, m. 192-4°);
     3-[2-phenylethylaminoethyl)methylamino]tropane, b1.6 182-7°, nD24
     1.5518.
     123935-68-2
        (Derived from data in the 6th Collective Formula Index (1957-1961))
RN
     123935-68-2 CAPLUS
CM
     Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3-nortropanyl)-2-thio-
```

(6CI) (CA INDEX NAME)

IT 102457-13-6P, Nortropane, 3-[(2-diethylaminoethyl)ethylamino]-8-phenyl- 102463-23-0P, Nortropane, 3-[(2-diethylaminoethyl)methylamino]-8-phenyl- 102709-02-4P, Nortropane, 3-[(2-diethylaminoethyl)amino]-8-phenyl- 110147-72-3P

- , Nortropane, 3-[N-(2-diethylaminoethyl)acetamido]-8-phenyl-RL: PREP (Preparation)
- (preparation of)
- RN 102457-13-6 CAPLUS
- CN Nortropane, 3-[(2-diethylaminoethyl)ethylamino]-8-phenyl- (6CI) (CA INDEX NAME)

- RN 102463-23-0 CAPLUS
- CN Nortropane, 3-[(2-diethylaminoethyl)methylamino]-8-phenyl- (6CI) (CA INDEX NAME)

$$\begin{array}{c|c} \mathtt{Ph-} & \mathtt{N} & \mathtt{N-CH_2-CH_2-NEt_2} \\ & \mathtt{Me} & \end{array}$$

- RN 102709-02-4 CAPLUS
- CN Nortropane, 3-[(2-diethylaminoethyl)amino]-8-phenyl- (6CI) (CA INDEX NAME)

- RN 110147-72-3 CAPLUS
- CN Nortropane, 3-[N-(2-diethylaminoethyl)acetamido]-8-phenyl- (6CI) (CA INDEX NAME)

L3 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1957:86037 CAPLUS

DOCUMENT NUMBER: 51:86037

ORIGINAL REFERENCE NO.: 51:15606g-i,15607a-c

TITLE: Heterocyclic alcohol diammonio esters

PATENT ASSIGNEE(S): Cutter Laboratories, Inc.

DOCUMENT TYPE: Patent
LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

GB 770581 19570320 GB 1955-8626 19550324
AB Esters containing two quaternary nitrogens, a trialkyl N being on the acid

moiety and a heterocyclic N on the alcohol moiety are useful as hypotensor agents. Thus, to make 2-(1-ethylpiperidinium)ethyl 3-(trimethylammonium)propionate diiodide (I), 10.0 g. 1-ethyl-1-(2-hydroxyethyl)piperidinium iodide (II) was first acylated 1 hr. with 26 g. I(EH2)2COC1 (III) on a steam bath. This product was washed with Et20, MeOH and then Et20 to yield a residue which was dissolved in an MeOH-dlowane (10 ml.:25 ml.) and mixed with 2.1 g. MeSN in 16 ml. dioxane.

MeOH-dioxane (10 ml.:25 ml.) and mixed with 2.1 g. Me3N in 16 ml. diox. After 3 days, 10.6 g. I, m. 169-71° (from MeOH), separated Directions

are given for similar reactions to yield the following 2-(substituted-ethyl)-3-(trimethylammonium)propionate diiodides

(substituent on C-2 of ethyl, yield and m.p., crystallization solvent given):

1-methylpiperidinium, 52%, 170-1°, MeOH-Et2O (IV); 1-methylpyrrolidinium, 81%, 190°, IV; 4-methylmorpholinium, 61%,

188-90°, MeOH. An alternative procedure was represented by

refluxing 10 g. 2-(4-methyl-1-piperidyl)-2-propyl 3-

(dimethylamino)propionate (V), in 500 ml. Me2CO 1 hr. with 20 g. MeI.

Upon cooling, the mixture yielded 16.3 g. 2-(1,4-dimethylpiperidinium)-2-propyl 3-(trimethylammonlum)propionate diiodide (VA), m. 170-2° (from wet MeZCO). II was prepared in 60% yield by refluxing 24 hrs. 13.5 g.

2-iodoethanol in 50 ml. MeOH with 9.0 g. 1-ethylpiperidine. The oily II which separated on cooling slowly solidified. Crystallization of this solid

from

Me2CO-MeOH (100 ml.:50 ml.) yielded 10.3 g. II, m. 240°.

1-(2-hydroxyethyl)-1-methylpiperidinium iodide, m. 235-8°, was similarly prepared in 93% yield. Equimolar quantities of 4-methylpiperidine and propylene oxide, when refluxed 4.5 hrs. and distilled, yielded 80% 1-(4-methyl-1-piperidyl)-2-propanol (VI), b. 210-12°. VI was slowly added to 1 mole acrylyl chloride in C6H6 and this mixture then refluxed 2.5 hrs. The C6H6 solution, after washing with cold saturated NaCl solution and excess Na2CO3 solution, yielded 69% 2-(4-methyl-1-piperidyl)-2-propyl acrylate (VII), b2.5 85°. When 1 mole gaseous Me2NH was passed into cold VII and this mixture held 17 days at room temperature (sealed tube), distillation (93-8° at 1.5 mm.) yielded V containing about 20% VII, satisfactory for producing VA. III (bl8 75-80°) was prepared in 75% yield by refluxing I(CH2)2CO2H (36 g.) with 14 ml. PC13 5 hrs. and distilling Using an ion exchange column (C1 form), I was converted to its dichloride, m. 200-1°. The dinitrate, m. 142°, and the dibitattrate, m.

123-6°, of I were prepared from I and the appropriate Ag salt. Picric acid and I yielded I dipicrate, m. 182-3°. In most examples, analyses are given.

IT 123935-68-2

(Derived from data in the 6th Collective Formula Index (1957-1961))

RN 123935-68-2 CAPLUS

CN Urea, 1-(2-diethylaminoethyl)-3-phenyl-1-(8-phenyl-3-nortropanyl)-2-thio-(6CI) (CA INDEX NAME)

=> d his

(FILE 'HOME' ENTERED AT 20:25:33 ON 22 FEB 2008)

FILE 'REGISTRY' ENTERED AT 20:25:48 ON 22 FEB 2008

L1 STRUCTURE UPLOADED 214 S L1 FULL L2

FILE 'CAPLUS' ENTERED AT 20:26:52 ON 22 FEB 2008 19 S L2 FULL L3

=> log y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION 104.51 283.54 FULL ESTIMATED COST DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY ENTRY SESSION -15.20 -15.20 CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 20:28:15 ON 22 FEB 2008